### UNIVERSITY<sup>OF</sup> BIRMINGHAM University of Birmingham Research at Birmingham

# Subtype-specific regulatory network rewiring in acute myeloid leukemia

Assi, Salam A.; Imperato, Maria Rosaria; Coleman, Daniel J. L.; Pickin, Anna; Potluri, Sandeep; Ptasinska, Anetta; Chin, Paulynn Suyin; Blair, Helen; Cauchy, Pierre; James, Sally R.; Zacarias-cabeza, Joaquin; Gilding, L. Niall; Beggs, Andrew; Clokie, Sam; Loke, Justin C.; Jenkin, Phil; Uddin, Ash; Delwel, Ruud; Richards, Stephen J.; Raghavan, Manoj

DOI: 10.1038/s41588-018-0270-1

*License:* None: All rights reserved

Document Version Peer reviewed version

Citation for published version (Harvard):

Assi, SA, Imperato, MR, Coleman, DJL, Pickin, A, Potluri, S, Ptasinska, A, Chin, PS, Blair, H, Cauchy, P, James, SR, Zacarias-cabeza, J, Gilding, LN, Beggs, A, Clokie, S, Loke, JC, Jenkin, P, Uddin, A, Delwel, R, Richards, SJ, Raghavan, M, Griffiths, MJ, Heidenreich, O, Cockerill, PN & Bonifer, C 2019, 'Subtype-specific regulatory network rewiring in acute myeloid leukemia', *Nature Genetics*, vol. 51, no. 1, pp. 151-162. https://doi.org/10.1038/s41588-018-0270-1

Link to publication on Research at Birmingham portal

#### **Publisher Rights Statement:**

This document is the Author Accepted Manuscript version of a published work which appears in its final form in Nature Genetics. The final Version of Record can be found at: https://doi.org/10.1038/s41588-018-0270-1

#### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.

• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

#### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

# Subtype-specific regulatory network rewiring in acute myeloid leukemia

- 3
- 4

Salam A. Assi<sup>1\*</sup>, Maria Rosaria Imperato<sup>1\*</sup>, Daniel J. L. Coleman<sup>1\*</sup>, Anna Pickin<sup>1</sup>,
Sandeep Potluri<sup>1</sup>, Anetta Ptasinska<sup>1</sup>, Paulynn Suyin Chin<sup>1</sup>, Helen Blair<sup>2</sup>, Pierre
Cauchy<sup>1</sup>, Sally R. James<sup>3</sup>, Joaquin Zacarias-Cabeza<sup>1</sup>, Liam Niall Gilding<sup>1</sup>, Andrew
Beggs<sup>1</sup>, Sam Clokie<sup>4</sup>, Justin C. Loke<sup>1</sup>, Phil Jenkin<sup>5</sup>, Ash Uddin<sup>5</sup>, H. Ruud Delwel<sup>6</sup>,
Stephen J. Richards<sup>7</sup>, Manoj Raghavan<sup>1,8</sup>, Michael J. Griffiths<sup>4</sup>, Olaf Heidenreich<sup>2</sup>,
Peter N. Cockerill<sup>1&</sup> and Constanze Bonifer<sup>1&</sup>

11

<sup>\*</sup>Equal contribution

13 **Corresponding authors** 

14

15

16 Acute myeloid leukemia (AML) is a heterogeneous disease caused by a variety of mutations 17 in transcription factors, epigenetic regulators and signaling molecules. To determine how 18 different mutant regulators establish AML subtype-specific transcriptional networks we 19 performed a comprehensive global analysis of cis-regulatory element activity and interaction, 20 transcription factor occupancy and gene expression patterns in purified leukemic blast cells. 21 Here, we focussed on specific sub-groups of patients carrying mutations in genes encoding 22 transcription factors (RUNX1, CEBPA) and signaling molecules (FTL3-ITD, RAS, NPM1). 23 Integrated analysis of these data demonstrates that each mutant regulator establishes a 24 specific transcriptional and signaling network unrelated to normal cells sustaining the 25 expression of unique sets of genes required for AML growth and maintenance.

#### 27 Introduction

28

29 Acute myeloid leukemia (AML) is characterized by blocked myeloid lineage differentiation 30 and accumulation of leukemic blast cells. AML is a highly heterogeneous disease caused by 31 different types of mutations affecting signaling pathways as well as transcriptional and 32 epigenetic regulators<sup>1-3</sup>. Recurrent mutations include loss of function mutations in 33 transcription factors (TFs) controlling hematopoietic development, such as RUNX1, GATA2 34 or C/EBP $\alpha^4$ , and gain of function mutations in signaling molecules such as FLT3, KIT, JAK2 and NRAS regulating inducible TFs such as NF-κB, STAT or AP-1 family members<sup>5,6,7</sup>. The 35 36 most common FLT3 mutations are internal tandem duplications (FLT3-ITD), which give rise 37 to a constitutively active growth factor receptor<sup>8,9</sup> and often occur together with 38 nucleophosmin1 mutations (NPM1). Another major group of mutations alters genes encoding epigenetic and chromatin regulators<sup>10,11</sup>. Genes belonging to this class play 39 40 widespread roles in development and differentiation by controlling establishment, 41 maintenance and extinction of lineage-specific gene expression programs. These include 42 regulators of histone and DNA methylation such as MLL, EZH2, BCOR, TET2, DNMT3A and IDH1/2<sup>11-17</sup>. In normal cells, all common mutation targets cooperate to control the finely 43 44 balanced gene expression changes essential for cell differentiation and lineage commitment.

45 TFs interact with defined target gene sequences and recruit epigenetic regulators to 46 program specific chromatin states and mediate the coordinated activation and de-activation of cis-regulatory elements driving gene expression<sup>18,19</sup>. Distal cis-regulatory elements 47 48 interact directly with proximal promoter elements, an arrangement that is both dynamic and robust<sup>20,21</sup>. From global studies examining a few selected types of AML we know that gene 49 50 expression patterns and the epigenetic landscape differ from normal cells<sup>22-27</sup>. However, how 51 the disruption of specific TF activity leads to a specific pattern of aberrant chromatin 52 programming and changes in gene expression in AML is unclear. We do not know at the

53 global level which cis-regulatory elements are affected in their activity in different types of 54 AML, how their activity is altered in patients carrying TF and signaling mutations, how such 55 differential activity relates to the differentiation block in primary cells of actual patients and 56 which factors maintain their transcriptional networks.

In this study we addressed these questions by collecting transcriptome, digital footprinting and chromatin conformation capture data from purified leukemic blasts from AML patients with defined transcription factor and signaling molecule mutations with the aim of defining the components of AML subtype-specific regulatory circuitries. Our study provides global insights into mutation-specific chromatin programming, and comprises a comprehensive resource of the transcriptional networks of different AML subtypes, highlighting pathways required for tumour maintenance

- 64
- 65

66 **Results** 

#### 67 AML with different mutant regulators adopt unique chromatin landscapes

68 In order to examine how specific TF and signaling mutations alter the epigenome of AML, 69 we purified CD34+ or CD117+ leukemic blast cells from bone marrow or peripheral blood 70 samples from a cohort of AML patients (Fig 1A). After determining the mutation status by 71 targeted sequencing and cytogenetics (Table S1), we selected a cohort of patients with 72 defined mutations in transcription factor, signaling and epigenetic regulator genes. Mutations 73 included: RUNX1 mutations affecting DNA-binding (D-type) or lacking the trans-activating 74 domain (T-Type), t(8;21) translocations fusing the DNA binding domain of RUNX1 to the co-75 repressor ETO, inv(16) which fuses CBF $\beta$  to smooth muscle myosin heavy chain 11 76 (MYH11) protein, independent mutations of both alleles of the CEBPA gene whereby at one mutation leads to loss of DNA-binding activity<sup>28</sup> and FLT3-ITD with or without NPM1 77 78 mutations. One of the patients carrying a RUNX1 mutation (RUNX1-T-7) who had Non-

79 Hodgkin Lymphoma (NHL) was included as an alternative class of patient. To identify AML-80 specific gene regulatory networks we performed high read depth DNasel-Seg (Fig.1B) and 81 RNA-Seq (Fig S1A) on 29 samples comprising seven major groups, and at least one 82 analysis on 12 additional samples, with mutations such as NRAS, CBL, JAK2, SRFS2, or 83 inv(3), as defined in Table S1. Samples were compared to CD34+ mobilized peripheral 84 blood stem cells (PBSCs) from the peripheral blood of two healthy individuals and to cord 85 blood (CB) CD34+ cells. To provide the community with a data resource, we established an 86 online database containing multiple data-sets including a genome browser (see Data 87 Availability).

88 Unsupervised clustering revealed that distal DHSs clustered in different groups 89 according to the class of mutations (Fig 1C). Samples with FLT3-ITD and/or NPM1 90 mutations represented one major group with sub-clusters for patients with NPM1 mutations 91 or carrying two FLT3-ITD alleles, but excluding a FLT3-ITD patient carrying a RUNX1 92 mutation. DHSs from the t(8;21), inv(16) and CEBPA double mutant patients clustered as 93 discrete groups within a larger group, indicating that these mutations affect similar pathways. 94 Examples of these patterns can be seen for DHSs in the POU4F1 locus in t(8;21) and 95 CEBPA-mutated samples, and DHSs in the FOXC1 locus in patients with FLT3-ID or NPM1 96 mutations (Fig. S1B). DHSs from patients with RUNX1 mutations were more heterogeneous 97 and formed a larger cluster together with the PBSCs and the inv(3) patients. The NHL 98 (RUNX1-T-7) and the NPM1/RAS sample were unrelated to any of the others. We further 99 validated our findings by including an independently derived published ATAC-Seq data-set 100 in our analysis<sup>25</sup>, confirming that mutations in FLT3 underpin one major component of the 101 clustering (Figure S2A). In contrast, the presence or absence of epigenetic mutations such 102 as DNMT3A did not influence chromatin accessibility levels (Fig. S2B) or gene expression 103 (data not shown).

104 Unsupervised clustering analysis of RNA-Seq data from the same patients (Fig S1C, 105 S2C) revealed strong correlations between mutation-specific accessible chromatin 106 landscapes and mutation-specific differential gene expression. This was again exemplified at 107 the POU4F1 and FOXC1 loci (Fig. S1D) where the mRNA patterns correlated well with the 108 chromatin profiles (Fig. S1B). We identified distinct patterns of expression for specific TF 109 genes in different AML types (Fig S2D), with, for example a number of homeo-domain gene 110 family members (HOX, NKX, IRX and PBX families) specifically up-regulated in the FLT3-111 ITD and NPM1-mutated patients. In summary, our comparative analyses show that aberrant 112 TFs and chronic signaling impose distinct mutation group-specific programs of chromatin 113 accessibility and gene expression, irrespective of the presence of other classes of mutations 114 such as DNMT3A.

115 We next investigated, whether the mutation class and its associated DHS pattern 116 correlated with a block at a specific stage of the differentiation. Here we again used published ATAC-Seq data<sup>25</sup> describing the open chromatin landscape of normal stem and 117 118 progenitor cells (Fig 2A). Our DNasel-Seq data correlated well with these data (Fig S3A and 119 S3B), whereby CD34+ PBSC sequences clustered with hematopoietic stem cells (HSCs) 120 and early progenitors but not monocytic cells. When compared to the various types of 121 progenitor cells, t(8;21), inv(16), CEBPA(x2) and NPM1-mutated AML displayed distal 122 element patterns most similar to those of normal GMPs, with some differentiation into 123 monocytes (Fig 2B). In contrast, RUNX1 and FLT3-ITD/NPM1 mutated AML displayed a 124 spread of lineage-specific patterns with little or no monocytic differentiation (Fig 2B). Gene-125 set enrichment analysis comparing the gene expression patterns of AML cells with the 126 various progenitor stages confirmed that the mutation-group specific cistrome was mirrored 127 by the gene expression pattern (Fig 2C). However, although AML subtypes showed some 128 characteristics of normal progenitor cells, they still clustered away from normal cells (Fig 129 S3B). Importantly, our mutation analyses showed no indications for the presence of

confounding major sub-clones in the purified undifferentiated AML cell population, as
mutations were present at close to either a 50% or a 100% allele frequency (Dataset S1).

132

### AML-specifically active cis-regulatory elements cluster into common and uniquegroups

135 We next examined which active cis-regulatory elements were specific for each AML subtype 136 and which TF families were responsible for their activation. To this end, we defined the union 137 of all AML-specific DHSs as compared to CD34+ PBSCs and performed k-mean clustering 138 to identify unique and common DHSs shared between patients, which identified 20 distinct 139 DHS clusters (Fig 3A). Less than half of these DHSs were found in any of the Corces et al.<sup>25</sup> 140 progenitor data ATAC-Seq sets and the percentage overlap varied substantially between 141 clusters (range 2 - 40%; Fig. 3C). These data indicated that AML cells did indeed reprogram 142 their chromatin and adopted a separate identity compared to all stages of normal myeloid 143 cells. We also verified mutation-specific clustering behaviour of our samples by comparing 144 them with a recently published AML histone H3K27 acetylation data set containing samples 145 with FLT3-ITD, RUNX1 and CEBPA double mutations. Mutation-specific cis-regulatory 146 elements from this study<sup>26</sup> largely overlapped with the mutation-specific DHSs identified here 147 (Fig. S3D). We then defined mutation specific groups of deregulated DHSs that were shared 148 between the specific members of each of the seven major mutation groups defined in Table 149 S1 (Figs. S4A and S4B) which were distributed between both the mutation-specific clusters 150 and the shared clusters (Fig 2B) and were associated with differentially expressed genes 151 (Dataset S2). As seen above in the clustering analysis, the t(8;21), inv(16), and CEBPA 152 groups showed similar patterns whereby 914 upregulated DHSs were shared between the 153 three groups (Fig. S4A). The FLT3-ITD, FLT3- ITD/NPM1 and NPM1 mutation groups also 154 showed substantial overlap with 942 shared DHSs, and with only 19% of these DHSs also 155 included in the 914 ITD/NPM1-specific DHSs. These AML-specific patterns showed little

similarity to normal myeloid differentiation as the majority of these specific sites were not up-regulated in GMPs relative to PBSCs (Supplementary note SN1B).

158 The presence of specific DHSs strongly correlated with the up-regulation of their 159 nearest genes (Dataset S3), indicating that AML type-specific cis-regulatory elements drive 160 the expression of AML type-specific genes (Fig S4C) as exemplified by a DHS at POU4F1 161 (Fig S4D). Fig S4E shows examples of AML-specific up-regulated genes of regulatory 162 relevance, including those encoding growth factor receptors or TFs which were associated 163 with the presence of AML type-specific DHSs, in this case NFIX, POU4F1, MEIS1 and 164 FOXC1 (Dataset S4). The gene expression patterns of such genes were validated using 165 publicly available data-sets (Fig S5).

166

### Mutation-specific cis-regulatory elements display specific transcription factor occupancy patterns

169 To identify TF motifs responsible for the establishment of the different patterns, we 170 performed digital footprinting analysis from high-read depth DNasel-Seg data using our 171 Wellington algorithm<sup>29</sup>. We began by creating a curated list of motifs based on several TF 172 databases (Table S2) since closely related factors typically recognise identical sequences. 173 We therefore selected single representative motifs for each of the different transcription 174 factor families, so as to remove redundant motifs bound by multiple factors. Examples of 175 footprints are depicted for NFI and ETS motifs at the MDFI locus in FLT3-ITD/NPM1-176 mutated AML (Fig. 4A) and for RUNX, NFAT and C/EBP motifs at the C3AE1 locus in t(8;21) 177 and CEBPA-mutated AML (Fig. S6A). The majority of AML type-specific DHSs within the 20 178 AML-specific DHS clusters contained footprints, as exemplified by a DHS at C3AE1 179 (Fig.S6B). For validation, we compared RUNX motif footprints with publicly available RUNX1 ChIP data from our studies (FLT3-ITD/NPM1<sup>24</sup>, t(8;21)<sup>30</sup>) and others (inv(16)<sup>31</sup>) (Fig.S6C). 180 181 Between 60% and 85% of footprinted RUNX motifs occurred in regions shown to bind

182 RUNX1. Additional motif enrichment analyses of up-and down regulated DHSs are shown in
 183 Supplemental Notes, Fig SN1 - 3.

184 We next evaluated occupied motifs for enrichment in any of the AML type-specific 185 DHSs defined by the 20 DHS clusters (Fig. 4B). This analysis showed that motif occupancy 186 patterns were highly AML type-specific. For example, the FLT3-ITD/NPM1-specific clusters 187 5 and 19 are enriched for occupied HOX, PBX, FOX/E-box and NFI motifs. Occupancy 188 correlated with up-regulation of multiple homeo-domain genes together with FOXC1 and 189 NFIX (Fig S2C). We have previously shown that AP-1 is a crucial mediator of FLT3-ITD signaling<sup>24</sup>. Occupied AP-1 motifs are enriched in multiple clusters (01, 05, 07, 12, 13, 18, 190 191 19), many of which come from AML with signaling mutations. The same is true for NF- $\kappa$ B 192 motifs which are enriched in clusters 01, 03, 06, and 08 which are shared amongst different 193 AML groups. NF- $\kappa$ B and AP-1 factors are mediators of MAP kinase signaling which points to 194 a wide-spread and specific activation of this signaling pathway not just in FLT3-ITD AML<sup>24</sup>, 195 but in other AML types. Composite ETS/E-box motifs are occupied in clusters 02, 17 and 20 196 (associated with the CBF/CEBPA groups), and also in clusters 03, 11 and 14. Finally, we 197 observed significant occupancy of the motif for POU4F1 in clusters 02 and 20 containing 198 samples from patients carrying the t(8;21) and CEBPA double mutations, but nowhere else (Fig4B). POU4F1 has been shown to be aberrantly expressed in t(8;21) cells<sup>32</sup>, but has so 199 200 far not been linked to CEBPA double mutations. A similar differential occupancy picture was 201 seen when footprints were clustered according to mutation-specific groups of DHSs (Fig. 202 S6D). Inspection of motif occupancy of C/EBP motifs in AMLs where both alleles of CEBPA 203 are mutated showed little, if any, reduction in overall motif occupancy, indicating a 204 compensatory action of other C/EBP family members (Fig S6D) which are expressed in 205 these cells (Dataset S4). This analysis connects the AML type-specific occupancy of the 206 motifs to the AML subtype-specific expression of defined sets of TFs and demonstrates that

207 their expression is of functional relevance for the programming of chromatin at their target208 genes.

209 To examine the position of transcription factor occupancy patterns within the 210 hematopoietic hierarchy, we correlated the presence of footprints specific for the different AML-subtypes with accessible chromatin regions present in precursor cells (Fig 4C)<sup>25</sup>. This 211 212 analysis revealed unique factor occupancy patterns of AML cells compared to normal 213 progenitor cell types. For example, HOX motifs within open chromatin regions observed in 214 HSCs, MPPs and MEPs are occupied in the FLT3-ITD/NPM1 and RUNX1 groups, but not in 215 the t(8;21) group, confirming the early block in differentiation (Fig 2B). Many of the samples, 216 including NPM1, FLT3-ITD/NPM1 and t(8;21) cells, also displayed high AP-1 motif 217 occupancy which is normally only seen in monocytes. POU4F1 is expressed in HSCs, MPPs, MEPs and in CLPs<sup>25</sup> and its binding motifs are occupied in t(8;21) and CEBPA 218 219 double mutant cells, yet these AML cells also show strong occupancy of C/EBP motifs, 220 which is normally a hallmark of GMPs and Monocytes.

In summary, our high-resolution digital footprinting analysis shows (i) that each AML subtype employs a different combination of factors binding to elements shared with different types of precursor cells and that (ii) lineage unrelated expressed TFs such as FOXC1, NFIX and POU4F1 participate in such cooperation.

225

### AML type-specific cis-regulatory elements show differential intra-chromosomal interactions mediated by shared and specifically expressed transcription factors

The construction of gene regulatory networks requires the linking of cis-regulatory elements to their respective promoter<sup>33</sup>. We therefore examined whether the differential activity of cisregulatory elements in different AML sub-types resulted in the formation of alternate ciselement interactions, and which TF families mediated such interactions. To this end we analysed cells from relapse patient sample t(8;21)-1R (Table S1), which maintained a gene

233 regulation network similar to the presentation sample t(8:21)-1 (Figs. 1C, S1C and S7A), 234 and a patient carrying a FLT3-ITD/NPM1 mutation (ITD/NPM1-2, Table S1) using promoter-235 capture chromosomal structure analysis (CHi-C) and compared these data to a dataset derived from human CD34+ cells<sup>34</sup>. Most interactions occurred intra-chromosomally and did 236 237 not differ at the global level (Fig. S7B). Fig 5A shows interactions across a segment of 238 chromosome 2, projected on the DHS pattern, demonstrating the organization of this this 239 region into topologically associated domains (TADs) that are separated by regions devoid of 240 DHSs. This higher-level structure was unaffected by the type of AML.

241 Intra-chromosomal interactions driving gene expression are mediated by 242 transcription factor complexes binding to cis-regulatory elements which exist as DHS. The 243 proportion of DHSs involved in AML type-specific interactions varied between the DHS-244 clusters (Fig 3A, Fig S7C). Moreover, ~40% of all promoters showing differential interactions 245 were associated with expressed genes (Fig S7D,E). Fig S7F shows a direct comparison 246 between the data from the two patients and demonstrates that differential interactions (i) 247 correlated with a differential DHS pattern and that (ii) this difference led to the expression of 248 a differential set of genes with different GO terms (Dataset S5). Fig S7G shows an example 249 of differential interactions within the KLF2 gene which is differentially expressed between 250 FLT3-ITD and t(8;21) and CD34+ cells.

251 On average 80% of all DHSs mapped in the t(8;21) AML, the FLT3-ITD AML and the 252 CD34+ cells participated in interactions (Fig S7H). An an average of 17% of interactions 253 were specific for each AML-type and not found in CD34+ PBSCs (Fig S7I), whereby half of 254 these were unique to the type of AML (Fig S7J). To identify the TF families involved in 255 regulating differential interactions we determined the proportions of enriched occupied motifs 256 in the DHSs underlying interactions (Fig S7K). These analyses revealed (i) that 257 hematopoietic TFs such as RUNX, ETS and C/EBP family members participated in 258 differential interactions in both AML types, together with the ubiguitously expressed inducible

AP-1 factor family and the normally invariantly binding CTCF factor and (ii) that AML
subtype-specifically expressed TFs participated in such interactions as well. In the FLT3-ITD
AMLs this included HOX proteins and factors occupying FOX/E-box motifs. In the t(8;21)
AMLs this included NF-κB and proteins binding to FOXO motifs as well as POU4F1, with
some motifs being differentially occupied in the same DHS cluster.

264

### Differential interactions drive AML subtype-specific expression of signaling genes but the majority of interactions are shared

267 In order to integrate differential interactions between promoters and DHSs, digital 268 footprinting data and gene expression data, we assigned the respective DHSs to the 269 promoter they interact with for the two patient classes as described in Fig 5B. We next used 270 these interactions to link DHSs to their respective promoters for AML type-specifically 271 expressed genes across all FLT3-ITD/NPM1 and t(8;21) patients as compared to CD34+ 272 PBSCs. This analysis revealed that the vast majority of DHS underlying interactions 273 between the three data-sets and those of individual patients were shared with an average 274 level of more than 80% overlap (Fig S8A) confirming earlier observations that the global 275 transcriptional network of related cells is also highly related<sup>35,36</sup>. Sub-type-specific DHSs 276 participating in interactions clustered within their patient group, and related groups, but not 277 with unrelated groups (Fig S8B), confirming that the two patients were representative for 278 those groups. For both the FLT3-ITD/NPM1 and the t(8;21) sample the nearest promoter 279 accounted for 65-74% of AML type-specific interactions driving the expression of genes that 280 are up-regulated compared to CD34+ cells (Figure 5C). Similar results were seen for each of 281 the 20 DHS clusters (Fig. S8C).

GO-term and KEGG-pathway analysis of expressed genes in the two types of AML (Fig 5D-G) revealed an AML type-specific core signature of genes being driven by specific cis-regulatory elements (for an extended gene list see Dataset S5). For both AML samples

285 these included genes involved in regulating pro-inflammatory pathways such as cytokine 286 receptor signaling and NF-κB signaling. FLT3-ITD cells also displayed an activated MAP 287 Kinase signaling signature whereas the t(8;21) signature also included RAP, RAS, PI3K and 288 FOXO signaling genes. Significantly, FOXO1 is already known to be part of the t(8:21) pre-289 leukemic maintenance program<sup>37</sup>. Importantly, more that 50% of all genes within these 290 pathways were targets of RUNX1-ETO (Figure 5H)<sup>30</sup> linking them to the actual driver 291 mutation. A similar percentage of the genes within the FLT3-ITD/NPM1 core pathway are bound by RUNX1 (Fig 5H) which is up-regulated in FLT3-ITD<sup>24</sup> (Dataset S5). This included a 292 293 number of growth factor receptor genes such as the normally T-cell specifically expressed 294 IL-2 receptor alpha chain which is specifically up-regulated in FLT3-ITD/NPM1 patients.

295 We noticed that ~83% of the DHSs which were involved in significant interactions in 296 each of the 3 samples (Fig S8D). We therefore merged all three CHi-C data-sets (Fig S8D) 297 to use this data to assign the DHS from the 20 clusters (Fig 3A) to their respective 298 promoters. The remaining 17% of DHS were assigned to the nearest promoter. Genes 299 associated with the DHS with confirmed interactions are listed in Dataset S6. GO-term and 300 KEGG-pathway analysis of such genes again showed activation of genes connected with 301 signaling processes such as an inflammatory response, regulation of MAPK activity and 302 cytokine regulation in all types of AML.

303

#### 304 Different types of AML are maintained by different transcription factor networks

305 Constitutive and inducible transcription factors form regulatory circuitries and networks by 306 interacting with their own/or other regulatory genes<sup>35</sup>. Cancer cells are capable of 307 maintaining a stable regulatory network over extended periods of time, implying that the 308 expression of each member of such a network is tightly controlled and remains in balance. 309 Consequently, perturbation of the network components maintaining this balance may 310 destabilize leukemic cells thus offering novel therapeutic options. We therefore combined

311 footprinting, TF gene expression and where possible, CHi-C data to construct transcription 312 factor networks in normal CD34+ cells and the different AML subtypes by linking occupied 313 binding motifs on TF genes to specific TF families. The full network structure for each cell 314 type without filtering can be studied in detail via the weblink (http://bioinformatics-315 bham.co.uk/tfinaml/). Comparison between the different AML subtypes and normal CD34+ 316 cells identified interactions between TF sets that were either shared between AMLs and 317 CD34+ cells (Fig. S9) or were specific for each subtype (Fig. 6). These analyses suggested 318 that the AP-1 family network, which is known to integrate multiple MAPK signalling 319 pathways, is of central relevance for leukemic maintenance in all AML subtypes (Fig 6 B-G). 320 Interestingly, in each case these networks reveal tight links between AP-1 and KLF family 321 members that form another node of general relevance in each AML. POU4F1 and HLH 322 family factors that recognising MYC/MAX type E-boxes formed prominent nodes in t(8:21) 323 AML only, while HOX proteins, FOXC1, NFIX and the MAF family were exclusively 324 highlighted in FLT3-ITD and NPM1mut-associated AML. Specific nodes and edges were 325 also part of the normal precursor program (Fig S9). For example the link between the C/EBP 326 family and NFIL3 was shared between the FLT3-ITD/NPM1 cells (Fig 6F) and CD34+ 327 PBSCs (Fig S9F). A detailed discussion of the different network structures and the role of 328 different TF families with more examples can be found in Supplemental Note 5.

329

#### 330 Network analysis identifies transcription factors contributing to AML propagation

We next used our network analyses to guide experiments validating the important role of TFs forming network nodes that were either widely employed in AML, or which were AML type-specific. To this end, we transduced three different AML cell lines and primary FLT3-ITD AML cells with lentiviral vectors coding shRNAs targeting *POU4F1* (specific for t(8;21)),or targeting *NFIX* or *FOXC1* (specific for FLT3-ITD), as well as control shRNAs. NFIX is known to play a role in myeloid lineage specification<sup>38</sup> but has not been linked to

specific mutation types. FOXC1 is an oncogene in its own right<sup>39</sup> and overexpression is 337 338 observed in AMLs with FLT3-ITD mutations<sup>24</sup>. However, NFIX and FOXC1 have not yet 339 been directly linked to the maintenance of the FLT3-ITD AML-phenotype. We applied two 340 distinct shRNA constructs per TF gene with all of them significantly reducing the 341 corresponding TF transcript and protein levels in FLT3-ITD and t(8;21) cell lines (Fig S10A-342 F). Knockdown of POU4F1 (Figs. S10 A and D) significantly inhibited the proliferation of 343 t(8;21)-positive Kasumi-1 cells (Figs. 7A and S10G) in agreement with our previous 344 findings<sup>32</sup>. Similarly, expression of NFIX shRNAs efficiently suppressed NFIX expression 345 (Figs. S10B and E) and significantly impaired the proliferation of FLT3-ITD-positive MV4-11, 346 but not FLT3-ITD-negative Kasumi-1 cells (Figs. 7B,C, S10H,I). We next tested the effect of 347 transduction of shRNA constructs targeting these genes on the colony forming ability of 348 patient CD34<sup>+</sup> cells carrying the FLT3-ITD/NPM1 mutations as well as on sorted CD34<sup>+</sup> 349 PBSCs. Importantly, both NFIX and FOXC1 shRNA constructs reduced the colony forming 350 ability of patient AML cells carrying the FLT3-ITD/NPM1 mutations, but not that of normal 351 CD34+ HSP cells (Figs. 7D, E).

352 In addition to subtype-specific TFs such as POU4F1 or NFIX, our network analysis 353 suggested that the AP-1 TF family is of general significance for all AML subtypes examined. 354 AP-1 is a heterodimer formed by members of the FOS, ATF, JUN and JDP families of 355 transcription factors and, consequently, challenging to target by defined RNAi approaches. 356 In order to interfere with the binding of all AP-1 family members, we introduced an inducible version of a dominant negative FOS (dnFOS) protein<sup>40,41</sup>. Doxycyclin-mediated induction of 357 358 dnFOS significantly inhibited proliferation of both t(8;21)-positive Kasumi-1 cells and FLT3-359 ITD expressing MV4-11 cell lines as compared to non-induced controls (Figs. 7F, G, S10J, 360 K). Moreover, transduction of primary CD34<sup>+</sup> FLT3-ITD cells with a lentivirus encoding a 361 constitutively expressed dnFOS reduced the colony forming ability of MV4-11 FLT3-ITD cells 362 but not of CD34<sup>+</sup> HPSCs (Figs. 7H, I, S10L). Finally, we examined the significance of AP-1

363 for leukaemia propagation in vivo. To that end, we transplanted either Kasumi-1 or MV4-11 364 cells expressing a doxycycline-inducible dnFOS into immunodeficient RG mice followed by 365 randomization into a doxycycline and untreated arm. In the case of Kasumi-1 366 transplantation, 6 out of 7 animals of the control group, but only 2 animals of doxycyclin-367 treated group developed granulosarcomas (Fig. 7J). Importantly, neither of the latter two 368 tumours expressed dnFOS after DOX treatment (data not shown), further suggesting that 369 induction of dnFOS was incompatible with tumour formation. Similarly, doxycycline treatment 370 of mice transplanted with FLT3-ITD MV4-11 cells that harbored the dnFOS transgene 371 inhibited the development of leukemia while all untreated mice rapidly developed tumours 372 and had to be sacrificed (Fig. 7K). Taken together, these findings demonstrate the 373 significance of AP-1 for several AML subtypes and emphasize the potential of transcriptional 374 network analyses to predict TFs crucial for malignant propagation.

375

#### 376 Discussion

377 In this study we define how aberrantly expressed TFs and signaling molecules shape the 378 epigenetic landscape of different sub-types of primary AML. We show (i) that it is possible to 379 use high-quality DNasel footprinting analysis of purified AML blast cells to identify AML 380 subtype specific TF networks, (ii) that such TF networks allow us to infer a dependency on 381 specific factors for leukemic growth and (iii) that the global activation of signaling pathways 382 in multiple types of AML parallels a growth dependency on AP-1 activity. This 383 comprehensive integrative comparison of gene expression patterns, chromatin accessibility 384 and TF occupancy of primary AML reveals a strong connection between leukemic classifier 385 mutations and networks of TFs and signaling components. Moreover, mapping of cis-386 element promoter interactions by CHiC enabled assigning the majority of genes of all 387 analysed subtypes to their correct promoter. It has long been known that different types of AML can be characterised by their gene expression and methylation patterns<sup>42,43</sup> suggesting 388

389 the existence of specific gene regulatory networks. However, our work now defines these 390 networks in detail, and convincingly proves that leukemic drivers determine the regulatory 391 phenotype by establishing and maintaining gene regulatory and signaling networks distinct 392 from normal cells. Networks consist of shared and specific components and even involve 393 regulators normally not expressed in myeloid cells, such as such as FOXC1 or POU4F1. 394 Our validation experiments show that induced and aberrantly expressed TFs are not just 395 bystanders, but are important for network maintenance and leukemic growth, thus 396 harbouring novel therapeutic opportunities for targeted treatment.

397 A clinically relevant novel finding from our study is that CEBPA double mutant AML is 398 epigenetically highly related to t(8;21) AML. The t(8;21) is driven by a single aberrant TF 399 (RUNX1-ETO) which is sufficient to establish a pre-leukemic state and whose mechanism of 400 action has been under scrutiny for many years. The most likely reason for this epigenetic 401 congruence between t(8;21) and CEBPA double mutant AML is that both mutations target a 402 common key control point of myeloid differentiation. RUNX1-ETO represses the CEBPA 403 gene while C/EBP $\alpha$  is required for the differentiation response of t(8:21) cells to RUNX1-404 ETO knock-down<sup>22</sup>. Consequently, the two types of AML share a number of pathways, as 405 exemplified by the expression of POU4F1, which could be translated into common 406 therapeutic strategies.

407 The full set of target genes of RUNX1-ETO in t(8:21) is known and the t(8:21) 408 specific epigenome and TF binding pattern has been extensively characterized<sup>44</sup>. A number 409 of target genes relevant for the maintenance or establishment of the leukemogenic state 410 have already been identified, including FOXO1, UBASH3B, POU4F1, and LAT2 together with the members of the RUNX1-ETO complex <sup>22,32,37,45-47</sup>. Our current comparative study 411 412 has validated these targets, highlighting the power of our methodology and has identified 413 multiple new network components. However, for the other types of AML, in particular for the 414 FLT3-ITD there had been insufficient knowledge of which genes and TFs are primarily

responsible for directing the AML type-specific gene regulatory networks. Here, we identified a number of signaling and transcriptional components distinguishing FLT3-ITD from normal blasts and from other types of AML comprising a rich resource for combination therapy approaches. We examined the contribution to leukemic growth for two genes with AML typespecific activity (*NFIX* and *FOXC1*) and showed that in every case their elimination resulted in a growth reduction in AML but not normal cells, yet again confirming that each type of AML stabilises a specific transcriptional network required for survival.

422 The AP-1 factor family has been known to play an important role in many types of tumours <sup>48</sup> and our study shows that it is also of major importance for different types of AML. 423 424 FLT3-ITD MV4-11 cells have abundant levels of nuclear AP-1, and FLT3-ITD target genes 425 such as CCNA1 are suppressed by MAP kinase inhibitors in these cells<sup>24</sup>. We have recently 426 shown that JUN scores highly in a siRNA dropout screen examining the requirements for 427 tumour development in t(8;21) AML (Martinez-Soria et al., in press). Moreover, FOS plays 428 an important role in the resistance against BCR-ABL inhibition in CML by activating 429 compensatory signaling pathways<sup>49</sup>. Since several growth factor and stress signal cascades 430 feed into AP-1, a targeted inhibition of all AP-1 binding may be less likely to lead to 431 resistance by rewiring of signalling pathways.

432 The classical picture of two-step leukemogenesis states that in AML a mutation 433 altering a differentiation trajectory cooperates with signaling mutations directing leukemic 434 growth<sup>10,11</sup>. Mutations in TFs which program chromatin directly, and epigenetic regulators 435 such as DNMT3A and TET2 which set up a specific global epigenetic landscape upon which 436 TFs act, fall into the first category while FLT3-ITD falls into the second. However, these 437 distinctions are now becoming blurred as from the viewpoint of the regulation of gene 438 expression, growth factor receptors elicit a strong influence on transcriptional activity via the 439 action of inducible TFs. Moreover, they play a dominant role in driving the differentiation 440 trajectory as their binding patterns, as exemplified by AP-1 family members, show an AML

441 sub-type specific occupancy signature that is uninfluenced by the presence or absence of epigenetic regulator mutations (in this case DNMT3A)<sup>24</sup>. This is not to say that mutations in 442 443 such genes do not influence the developmental trajectory of AML and clinical outcomes, as shown in CBF AML<sup>50</sup> since AML cells with such mutations acquire an altered DNA 444 445 methylation landscape that is likely to influence TF binding<sup>51</sup>. However, our data show that 446 the leukemic phenotype and self-renewal in different types of AML defined by differentially 447 activating a multitude of different and often lineage-unrelated signaling pathways and by 448 expressing lineage-unrelated TFs. From the viewpoint of finding therapeutic targets, 449 identifying such mutation-specific pathways will offer to eliminate their specific maintenance 450 program by targeting multiple pathways simultaneously. Our study provides a first step 451 towards this goal.

#### 452 Methods

#### 453

#### 454 **Patient samples and PBSC cell processing**

455 Human tissue was obtained with the required ethical approval from the NHS National 456 Research Ethics Committee. AML and PBSC samples used in this study were either surplus 457 diagnostic samples, or were fresh samples obtained with specific consent from the patients. 458 AML samples were obtained from either (i) the Haematological Malignancy Diagnostic 459 Service (St James's Hospital, Leeds, UK, (ii) the Centre for Clinical Haematology, Queen 460 Elizabeth Hospital Birmingham, Birmingham, UK, (iii) the West Midlands Regional Genetics 461 Laboratory, Birmingham Women's NHS Foundation Trust, Birmingham, UK, or from iv) 462 Erasmus University Medical Center, Rotterdam, The Netherlands. Mononuclear cells were 463 purified on the same day that they were received, and in most cases also directly further 464 purified using either CD34 or CD117 (KIT) magnetic antibodies, as previously described <sup>24</sup>. 465 For some samples with greater than 92% blast cells the column purification was not 466 performed. Mobilized PBSCs were provided by NHS BT, Leeds, and NHS BT, Birmingham.

#### 467 **Mutation detection**

468 Mutated genes identified in each patient are summarized in Supplementary Table 1, 469 together with the age, gender and white blood cell count for each patient. Mutations were 470 identified by one of two different methods. The first batch of patients were assayed by 471 targeted exon sequencing of 55 cancer-associated genes using 1212 pairs of previously 472 defined PCR primers <sup>24</sup> for amplification using a RainDance Technologies platform. The 473 mutation sequence data from this screen was analyzed using algorithms to detect either (i) nucleotide variants using the Genome Analysis Toolkit (GATK)<sup>52</sup> or insertions and deletions 474 475 using Pindel <sup>52</sup>. Mutations were also screened against the COSMIC database of previously 476 observed mutations (http://cancer.sanger.ac.uk/cosmic/). Subsequent samples were 477 assayed using the Illumina Trusight myeloid panel of primers and processed by approaches

- 478 similar to those used for the first batch. All identified mutations are listed in Table S1. Some
- 479 of these patients were also included in a previous publication from our laboratory, using

480 different patients identification codes <sup>24</sup> to those used in the current study.

481 Cell lines

482 Cell lines were cultured in an incubator at 37<sup>o</sup>C in GIBCO<sup>™</sup> 1640 RPMI + Glutamax<sup>™</sup>
483 medium supplemented with 10% heat inactivated fetal calf serum (GIBCO), 100 U/mI
484 Penicillin, 100 mg/ml Streptomycin.

#### 485 **Growth curve measurements**

486 250000 MV4-11 or Kasumi-1 cells were cultured in RPMI supplemented with 10 % fetal calf 487 serum, 2mM L-Glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. Cells were 488 counted with Trypan Blue exclusion and split every 3 days to maintain them in the log phase 489 of growth. For the inducible dnFOS, cells were counted and split every 2 days and 1.5 µg/ml 490 of doxycycline was added.

#### 491 **Co-culture of Primary Cells with MS-5 feeders**

492 Primary cells were maintained in co-culture with MS-5 cells <sup>53</sup> Briefly, cells were cultured in 493 LTC medium (α-minimum essential medium (Lonza) supplemented with heat-inactivated 494 12.5% fetal calf serum (Gibco), heat-inactivated 12.5% horse serum (Gibco), penicillin and 495 streptomycin, 200 mM glutamine, 57.2  $\mu$ M β-mercaptoethanol (Sigma) and 1  $\mu$ M 496 hydrocortisone; (Sigma) supplemented with 20 ng/ml IL-3, granulocyte colony-stimulating 497 factor (G-CSF) and thrombopoietin (TPO) in flasks pre-coated with MS-5 cells.

### 498 Lentiviral transduction and shRNA treatment

LEGO-iG-shRNA were generated by cloning shRNAs with the target sequences described below into the LEGO-iG vector<sup>54</sup>. LEGO-iG-dnFOS was generated by cloning the dnFOS insert, originally generated by Charles Vinson (National Cancer Institute, Bethesda, USA <sup>40</sup> into the LEGO-iG backbone. Inducible dnFOS was cloned into a pENTR backbone and then using Gateway Cloning to insert that into the Tet-on plasmid pCW57.1 (David Root,

Addgene plasmid #41393). Backbone vectors LEGO-iG and Inducible dnFOS then used to
generate lentiviral particles using packaging and envelope genes on four separate plasmids:
TAT, REV, GAG/POL and VSV-G<sup>55</sup>.

507 shRNATarget sequences: shFOXC1 B GTCACAGAGGATCGGCTTGAA; shFOXC1 C 508 GCCGCACCATAGCCAGGGCTT; shNFIX B: GGAATCCGGACAATCAGAT; 509 shNFIX C GCAGTCTCAGTCCTGGTTCCT; shPOU4F1 C 510 GCCGAGAAACTGGACCTCAAA; shPOU4F1: GCCGATTAACAAGACTGAAAT; 511 shMM GCGCGATAGCGCTAATAATTT

512 For virus production, 293T Human Embryonic Kidney cells were cultured in Dulbecco's 513 Modified Eagle Medium supplemented with 10 % fetal calf serum, 2mM L-Glutamine, 100 514 U/ml penicillin, 100 mg/ml streptomycin and 0.11 mg/ml Sodium pyruvate; and were seeded 515 to achieve 70-80% confluency at time of transfection. HEK293T cells were transfected using 516 the calcium phosphate co-precipitation of the five-plasmids (LEGO-iG with TAT, REV, 517 GAG/POL and VSV-G) at a mass ratio of 24  $\mu$ g : 1.2  $\mu$ g : 1.2  $\mu$ g : 1.2  $\mu$ g : 2.4  $\mu$ g per 150 518 mm diameter plate of cells. Viral supernatant was harvested after 24 h and subsequently 519 every 12 h for 36 h prior to concentration with Centricon Plus 70 100 kDa filter (Millipore, 520 USA), using the manufacturer's instructions. Concentrated viral particles were stored at 4 °C 521 prior to lentiviral transduction. Cell lines were transduced with concentrated virus in the 522 presence of 8 µg/ml polybrene by spinoculation at 1500 xG for 50 min. After 12 – 16 h 523 incubation at 37 °C viral media was exchanged for fresh media. Cell sorting by FACS was 524 performed to isolate GFP+ cells 3 days after transduction.

525 Primary cell samples were defrosted 24 h prior to transduction and co-cultured with MS-5 526 feeder cells in LTC medium. 6 well non-tissue culture treated plates were coated with 24 527 µg/ml retronectin (Takara Clontech) for 2 h prior to blocking with 2% BSA PBS for 30 min. 528 The blocking buffer was washed off with HBSS (Gibco) containing 2.5% HEPES. 1 ml viral 529 concentrate was applied to the retronectin coated plate by centrifugation at 2000 xG for 45

530 minutes, after which the concentrated viral supernatant was refreshed and the centrifugation 531 repeated. Primary cells suspended to a concentration of 1 x 106 cells/ml in the remaining 532 viral supernatant; supplemented with 20 ng/ul G-CSF, IL-3, TPO and 8  $\mu$ g/ml polybrene, 533 were then added to the plate and transduced by spinoculation at 1500 xG for 50 min. After 534 12 – 16 h incubation at 37 °C viral media was exchanged for fresh media. Cell sorting by 535 FACS was performed to isolate GFP+ cells 3 days after transduction.

#### 536 **Colony Formation Assays of Primary Cells**

537 Colony formation assays were performed on sorted cells by seeding at 2500 cells/ml in
538 Methocult Express (Stem Cell Technologies). After 14 days colonies were counted.

#### 539 Animal experiments

540 Immunodeficient Rag2<sup>-/-</sup>II2r $\gamma^{-/-}$ 129×Balb/c (RG) mice were housed in the Comparative 541 Biology Centre (Newcastle University) under specific pathogen free conditions. All animal 542 work was conducted in accordance with Home Office Project License PPL60/4552 by 543 researchers who had completed approved Home Office training and held current Personal 544 Licenses under the Animals (Scientific Procedures) Act 1986. Kasumi-1 pCW57.1-dnFOS 545 cells were intrahepatically injected into 14 newborn (2 days old) RG mice at a cell dose of 546 2.5x10<sup>5</sup> cells/mouse as described previously (Martinez Soria et al., 2009). Twelve days later, 547 mice were randomized into two treatment groups, one given doxycycline 50 mg/kg three 548 times per week intraperitoneally in an unblended fashion till the experimental endpoint. MV4-549 11 pCW57.1-dnFOS cells were intrafemorally injected into RG mice at a cell dose of 5x10<sup>5</sup> 550 cells/mouse followed by randomization into two groups. For the dox group doxycycline was 551 added at a concentration of 2 mg/ml for the initial 3 days and at 0.2 mg/ml subsequently to 552 drinking water containing 2% sucrose. Controls were given water containing 2% sucrose. 553 Animals were humanely killed upon clinical signs of illness or at defined experimental 554 endpoints.

555 **RT- qPCR** 

556 RNA was extracted using the Machery-Nagel Nucleospin kit. 1µg RNA was used to make 557 cDNA with 0.5µg OligoDT primer, Murine Moloney Reverse Transcriptase and RNase 558 Inhibitor (Promega, USA) according to manufacturer's protocol. RT-PCR was performed 559 using Sybr Green mix (Applied Biosystems, UK), at 2x dilution. Primers were used at 560 100nM concentration. A 7900HT system (Applied Biosystems, UK) was used to perform 561 qPCR. Analyses were performed in technical duplicates using a standard curve derived from 562 the untreated cell line.

#### 563 Western Blotting

564 Protein lysates from cell lines were analysed by Western blot. Relevant primary antibodies 565 against FOXC1 (Cell Signaling Technology - #8758), NFIX (Invitrogen - #PA5-31234), 566 POU4F1 (Santa Cruz Biotechnology - sc-8426) were used to detect target genes and 567 GAPDH (mouse  $\alpha$ GAPDH – Abcam – ab8245; rabbit  $\alpha$ GAPDH – Cell Signaling Technology 568 - 2118L) was used as a housekeeping gene. Secondary antibodies mouse anti-rabbit HRP 569 (Rockland – 18-8816-31) and goat anti-mouse HRP (Jackson ImmunoResearch – 115-035-570 062) enabled detection and quantifications by densitometry using Imagelab software and a 571 GelDoc imager.

#### 572 **RNA-Seq library preparation**

573 RNA was extracted and analyzed from purified AML cells as previously described <sup>23</sup>

#### 574 **DNasel-Seq**

575 DNasel digestions of permeabilized cells were performed as previously described<sup>56</sup>. Briefly,

576 live cells were added directly to a solution of DNasel (DPFF, Worthington) in dilute Nonidet

- 577 P40, digested for 3 min at 22°C, and the reactions then terminated by addition of SDS to
- 578 0.5%. DNasel was typically used in the range of 2-6  $\mu$ g/ml using a final 1.5 x 10<sup>7</sup> cells/ml.
- 579 DNasel-Seq libraries were then prepared and validated essentially as previously described
- 580 <sup>30</sup>. Libraries were run on Illumina sequencers.
- 581 **Promoter capture HiC (CHi-C) from patient AML blasts**

582 AML cells from patient peripheral blood were first purified by density gradient centrifugation 583 (Lymphoprep<sup>™</sup>) and then using CD34 antibody coupled beads. 5× 10<sup>7</sup> t(8;21) blasts (patient 584 t(8;21)-1R) and FLT3-ITD/NPM1 blasts (patient ITD/NPM1-2) were fixed in 37 ml of RPMI-585 1640 supplemented with 15% FBS and 2% formaldehyde for 10 minutes at room 586 temperature. 6 ml of 1M glycine (0.125 M final concentration) was added to quench the 587 reaction and cells were incubated at room temperature for 5 min, followed by 15 minutes on 588 ice before pelleting the cells at 4 °C and washing them in ice cold PBS. Each sample was 589 flash frozen in liquid nitrogen, and stored at -80 °C. Cells were lysed in a tight dounce 590 homogeniser (ten cycles) with 3ml of cold lysis buffer (10 mM Tris-HCl pH 8, 10 mM NaCl, 591 0.2% Igepal CA-630, one tablet protease inhibitor cocktail (Roche complete, EDTA-free, 592 11873580001)). Cells were left on ice for five minutes then homogenised another ten times. 593 The lysed cells, in 3 ml lysis buffer, were added to 47ml of lysis buffer and incubated on ice 594 for 30 minutes with occasional mixing. Chromatin was pelleted and resuspended in 1ml of 595 1.25x NEBuffer 2 and split into four. Each sample was then pelleted at 1000 rpm and 596 resuspended in 358 µl of 1.25x NEBuffer 2. 11 µl 10% SDS was added and each tube was 597 incubated at 37°C for 60 minutes, rotating at 950 rpm. Samples were mixed by pipetting up 598 and down every 15 minutes. SDS was guenched with 75µl 10% Triton X-100 and incubated 599 at 37°C for 60 minutes. HindIII digestion, biotinylation, ligation, crosslink reversal, promoter capture and library preparation was performed exactly as described in<sup>34</sup>. 600

601

#### 602 **Bioinformatics analyses**

#### 603 **DNasel-Seq data analysis**

Alignment: DNasel-seq sequences from all experiments were mapped onto the reference
 human genome version hg38, with Bowtie version 2.3.1<sup>57</sup> using default parameters. Low
 quality reads were trimmed prior to the alignment and the quality control (QC) statistics for

the samples were obtained using FastQC tools. Reads that were aligned to uniquechromosomal positions were retained.

609 **Peak calling**. DNasel Hypersensitive Sites (DHSs) were called with MACS2 using callpeak 610 function (nomodel, call-summits and q= 0.005 parameters)<sup>58</sup>. DHSs were allocated to genes 611 and to the gene promoter if it was within 2kb of the gene transcription start site (TSS), and 612 as distal otherwise. Overlaps between DHSs peaks were defined by requiring the summits of 613 two peaks to lie within +/-200 bp.

614 DNasel-Seq peak set definition: To define a common set of coordinates covering all of the 615 significant distal DHSs investigated in this study, we merged all of the individual DNasel-Seq 616 reads for all of the AML samples assayed by DNasel-Seq. This data set was then used to 617 define the peak summits of 128,864 distal peaks, excluding promoters, which were detected 618 in the merged data. This approach was designed to maximize the precision and sensitivity of 619 the peak detection, allowing us to generate a single set of peak coordinates that (i) included 620 all the regions where peaks might be found, thereby reducing the level of false negatives, 621 and (ii) greatly diminished the number of false positives. The DNA read counts were then 622 determined for 400 bp windows centered on each peak for each AML sample and for the 623 PBSC samples. To account for the different number of reads in each of the samples; the read counts were initially normalized for total read depth using DEseq2 59. Because most of 624 625 our individual DNasel-Seg data sets encompassed in the range of 25,000 to 40,000 626 significant distal DHSs, we further normalized the values obtained on the basis of the 627 midpoint (12.5 percentile) of the top 25% of peaks (32,216 peaks).

628 *Mutation-specific DNasel-Seq peak set definition:* We determined the average log2 629 values for 7 distinct subsets of AMLs that carried the same specific mutations in key 630 regulators, and which shared similar patterns of DHSs based on the DHS clustering analysis. 631 The samples included in each group are color-coded and listed in order in Table S1 for AML 632 samples with the following mutations: (i) 3 samples with FLT3-ITD but not NPM1 (#1 to 3), (ii)

633 6 samples with FLT3-ITD and NPM1 (# 1 to 6), (iii) 2 samples with NPM1 but not FLT3-ITD 634 (# 1 and 2), (iv) 4 samples with t(8;21) (1 to 4), (v) 3 samples with inv(16) (# 1 to 3); (vi) 6 635 samples with RUNX1 or RUNX1 and CEBPA (1 to 6), and (vii) 3 samples with 2 CEBPA 636 mutations (#1 to 3). To define mutation-specific subsets of specific DHSs, we identified 637 peaks where the average log2 value both was at least 64 and at least 3-fold higher than in 638 PBSCs. Downregulated DHSs are defined as being at least 3-fold less than in PBSCs. 639 Samples were not included in these 7 specific groups in cases where, for example, 2 copies 640 of the FLT3-ITD mutation were present, the NPM1 mutation was paired with a NRAS instead 641 of the FLT3-ITD, RUNX1 mutations were paired with a JAK2 mutation, or where only a 642 single CEBPA allele was mutated.

643 *Clustering of DNasel-Seq data:* Clustering of DNasel-seq samples was carried out using 644 the merged distal DHSs. The number of reads that mapped to these DHSs was counted in a 645 400bp window centered on the DHS summit, and subsequently normalized to total sample 646 size using DEseq2 <sup>59</sup>. Pearson correlation coefficients were then calculated for each pair of 647 samples using the log2 of the normalized read counts, and then hierarchically clustered 648 using Euclidean distance and complete linkage clustering of the correlation matrix in R.

649 K-mean clustering of AML specific DHSs: A combined set of up-regulated distal DHSs 650 that defined as being at least 3-fold greater than in PBSCs was used to perform 651 unsupervised k-mean clustering. The number of reads that mapped to these peaks was 652 counted in a 400bp window centered on the DHS summit, and subsequently normalized to 653 total sample size using DEseq2<sup>59</sup>. Clustering was done on rows (DHSs) while samples 654 (columns) were ranked based on the hierarchical clustering in Figure 1C. Initially the read counts output from DEseq2<sup>59</sup> was further quartile normalised using the "preprocessCore" 655 656 package in R, The log2 of the normalised reads were clustered using k-means clustering 657 with Euclidean distances (stats package in R) and the optimal number of clusters was 658 determined to be 20 based on the lowest Bayesian Information Criterion (BIC) scores

659 (Schwarz, 1978). Each of the 20 clusters was then hierarchically clustered using the660 "complete linkage" agglomeration method.

#### 661 ATAC sequencing data analysis

ATAC-seq profiles of hematopoietic and leukemic cell types taken <sup>25</sup> were downloaded from 662 663 GEO with accession number GSE74912. ATAC-seq data of HSC, MPP, CMP, CLP, MEP, 664 GMP and Monocytes were downloaded and aligned to the human genome version hg38. 665 Aligned reads with the same cell line were merged and then ATAC peaks were obtained 666 using MACS2 with default parameter. Overlaps between DHS and ATAC peaks were 667 defined by requiring the summits of two peaks to lie within +/-200 bp. Pair-wise peak 668 overlaps between DHSs and ATAC peaks of hematopoietic *i* and *j* were performed in order 669 to calculate the fraction  $(M_{ii})$ 

670  $M_{ij} = \frac{N_{ij}}{N_i}$  where  $N_{ij}$  is the total peaks that overlap,  $N_i$  is the total number peaks in set i 671 (DHSs) and  $N_j$  is the total peaks in j (ATAC). A matrix with the calculated fraction multiply by 672 100 was generated and a heatmap was plotted (Figure 2B) after hieratically clustered in R. 673 Clustering of DNasel-seq and ATAC-seq samples (Figure S2A and Figure S3B) was carried 674 out using the merged distal DHSs as described earlier using the DNasel-seq only.

#### 675 ChIP sequencing data analysis

676 ChIP-Seq sequencing reads were downloaded from GEO with accession numbers (GSM1581788, GSM1693378, GSM1466000)<sup>24</sup> (GSM722705, GSM722704)<sup>30</sup>, the reads 677 were aligned to the human genome version hg38 with Bowtie version 2.3.1<sup>57</sup>. Reads that 678 679 mapped uniquely to the genome were retained and duplicated reads were removed using 680 the MarkDuplicates function in Picard tools (http://broadinstitute.github.io/picard/). Peaks were identified with MACS version 1.4.2 58 and DFilter software 60 with recommended 681 682 parameters (-bs=100 -ks=50 -refine). Peaks common to both peak calling methods were 683 considered for further analysis.

#### 684 H3K27Ac ChIP data analysis

H3K27Ac ChIP data from<sup>26</sup> were downloaded from NCBI with accession number
SRP103200. The raw reads were aligned to the human reference genome hg38 and density
profiles were generated using *bedtools. The bedGraph* files were used to generate the
H3K27Ac average coverage plotted a long side the DHSs of the 20 clusters (Figure S3D).

#### 689 **Digital genomic footprinting**

Digital genomic footprinting was performed using the *Wellington\_footprints* function of the Wellington algorithm<sup>29</sup> on High-depth AML and CD34+ PBSC DHSs. DHS footprints probability and DNase forward and reverse cut coverages, were generated using the *dnase\_wig\_tracks* function of Wellington. AML-specific footprints compared to PBSC CD34+ cells were identified using *wellington\_bootstrap* function of Wellington. Mutation-specific footprints of the groups were identified by using the *Wellington\_footprints* function using the merged reads of the Mutation-specific individual DNasel-Seq of each group.

#### 697 **Motif identification**

De novo motif analysis was performed on peaks using HOMER<sup>61</sup>. Motif lengths of 6, 8, 10, and 12 bp were identified in within  $\pm$  200 bp from the peak summit. The annotatePeaks function in HOMER was used to find occurrences of motifs in peaks. In this case we used known motif position weight matrices (PWM).

702 Motif co-localisation clustering: Motif co-localisation clustering was performed as 703 previously described<sup>22</sup>. A motif position search was done within DHSs that are group 704 mutation-specifically footprinted. The distance between the centres of each motif pairs was 705 calculated and the motif frequency was counted if the first motif was within 50bps distance 706 from the second motif. Z-scores were calculated from the mean and standard deviation of 707 motif frequencies observed in random sets using bootstrap analysis, peak sets with a 708 population equal to that of the footprinted peaks were randomly obtained from the merged 709 footprints of all AML and CD34+ footprints sets. Motif search and motif frequencies

710 calculations were repeated 1000 times for each random set. A matrix was generated and Z-

scores were displayed after hierarchical clustering as a heatmap with R.

#### 712 Motif enrichment

To identify motifs that are relatively enriched in the distal footprinted DHSs of each of AML mutation groups (Figure S5) and the AML DHSs clusters (Figure 3A). For a given set *j* of footprints, we defined a motif enrichment score (ES<sub>ii</sub>) for motif *i* in footprint set *j* as

 $ES_{ij} = \frac{n_{ij}/M_j}{\sum_i n_{ij}/\sum_i M_i}$  where  $n_{ij}$  is the number of footprints in each subset j (j=1,2,...,12) 716 717 containing motif *i* (*i*=1, 2,...,*l*), *I* is the total number of motifs used in the test, and *M<sub>i</sub>* the total 718 number of peaks in each subset j (j=1,2,...,30). A matrix was generated and the motif 719 enrichment scores were displayed as a heatmap after hierarchical clustering with Euclidean 720 distance and complete linkage. The heatmap was generated using R. The statistical 721 significance for a ES<sub>ii</sub> score of a given motif i in peak set j is computed as Z-scores using 722 bootstrapping (N=1000), where a random set of peaks is extracted from a global set of 723 footprinted regions and ES is calculated. After N iterations the mean ( $\mu_{ii}$ ) and the standard deviation ( $\sigma_{ij}$ ) are computed and the z-scores are computed as  $Z_{ij} = \frac{ES_{ij} - \mu_{ij}}{\sigma_{ij}}$ . The global set 724 725 of regions is a merged set of all the AML footprints. These Z-scores are provided in Table 726 S7.

#### 727 RNA-seq data analysis

RNA-Seq reads were aligned to the human genome hg38 build with STAR<sup>62</sup> using ENCODE recommend parameters. Separate density profiles for the positive and negative strand were generated using bedtools. Cufflinks<sup>63</sup> was used to calculate the expression values as Fragments Per Kilobase per Million aligned reads (FPKM) from the aligned RNA-seq data. Mutation-specific group's gene-wise expression values were obtained using the *cuffdiff* function of cufflinks. The correlation between any two AML samples was obtained as the Pearson correlation coefficient of expression values over all genes. A correlation matrix was

thus generated for all the samples and hierarchically clustered to study the relationship
among samples as given in Figure S1C. Smooth scatter plots were generated in R.

#### 737 Gene expression analysis

Differentially expressed genes were extracted using the limma R package<sup>64</sup>. Genes were 738 739 said to be differentially expressed (DE) if there was a twofold change in expression between 740 any each of the AML patient sample or each of the mutation-specific group and the PBSC 741 CD34+ with a p-value less than or equal to 0.01 and with FPKM greater than 1 in at least 742 one AML sample. For each value of a DE gene a pseudo-count  $\gamma = 0.1$  was added to the 743 FPKM values and the binary logarithm of this value was considered as the expression value 744 of the gene in each sample (j),  $e_{ii} = log_2(FPKM_{ii} + \gamma)$ . These DE values were then 745 clustered (Figure S1A) using hierarchical clustering with Euclidean distances (stats package 746 in R). While Hierarchical clustering of transcription factors gene expression was carried out 747 on fold-changes for genes associated with at least a 2-fold change compared to the CD34+.

#### 748 Gene set enrichment analysis

A publically available RNA-seq data of hematopoietic cell types were downloaded from GEO with accession number GSE74246. The downloaded RNA-seq data were processed in similar way as described above. The GSEA software<sup>65</sup> was used to perform gene set enrichment analysis on group of genes. Module map<sup>66</sup> implemented by Genomic software was used to find which groups of genes are significantly up- or down-regulated using a statistical test based on the hyper-geometric distribution the fraction of up or down regulated is displayed as a heatmap (Fig 2C and Fig S4C).

**Gene ontology (GO) analysis:** Gene ontology (GO) analysis was performed using clueGO tools<sup>65</sup> with Hypergeometric for overrepresentation and Benjamini and Hochberg (FDR) correction for multiple testing corrections. KEGG Pathway network analysis was performed using clueGO tools<sup>65</sup> with kappa score = 0.3. A right-sided enrichment (depletion) test based on the hypergeometric distribution was used for terms and groups. The size of the nodes

reflects the number of genes within the term. The color of nodes reflects the enrichment
significance of the terms. The network is laid out using Cytoscape. The KEGG pathway
network figures for all DHS-cluster associated genes are shown in Table S6.

#### 764 Expression profiles from larger patient cohort datasets

Microarray data from Verhaak et al.<sup>42</sup> were downloaded from GEO under the accession number GSE6891. Patients were split according to their mutational status; Boxplots showing the expression of the indicated genes in FLT3-ITD, NPM1, CEBPA, t(8;21), inv(16) and NRAS mutation groups. The statistical significance of the difference in expression between FLT3-ITD and other mutations was determined using an unpaired t-test.

#### 770 **Promoter Capture HiC data analysis**

771 The CHi-C paired-end sequencing reads from ITD/NMP1-2 and t(8;21)-1R patients and a 772 publically available CD34+ dataset (accession numbers ERR436032 and ERR436025) were 773 put through *HiCUP* pipeline<sup>67</sup>. The raw sequencing reads were separated and mapped 774 against the human genome (hg38). The reads were then filtered for experimental artefacts 775 and duplicate reads, and then re-paired. Statistically significant interactions were called 776 using GOTHiC package<sup>68</sup> and HOMER software. This uses a cumulative binomial test to 777 detect interactions between distal genomic loci that have significantly more reads than 778 expected by chance, by using a background model of random interactions. This analysis 779 assigns each interaction with a p-value, which represents its significance. Differential interactions were determined with HOMER<sup>61</sup> for t(8;21) using FLT3-ITD or CD34+ as 780 781 background and FLT3-ITD using t(8;21) or CD34+ as a background. A difference with a p-782 value of less than 0.1 was deemed to be significant

#### 783 Transcription Factor Gene Regulatory Network Construction

We identified a subset of 310 transcription factor (TF) genes that are expressed in one or more of our AML samples. The gene names for transcription factors in human were obtained from AnimalTFDB<sup>69</sup>. The 310 TFs were considered as nodes and the nodes coloured

according to their expression values at each AML subtype (Fig 6, Fig S9 and Fig SN5). Node border colour signifies whether the gene is up-regulated, down-regulated or invariant base on a 2-fold-change compared to CD34+ cells. Node border type indicates whether gene is differentially expressed in one AML subtype as compared to other subtypes. A directed edge from  $TF_a$  to  $TF_b$  indicates motif binding of a  $TF_a$  to the locus of the  $TF_b$  and the edge is prominently displayed if  $TF_a$  binds to the locus at that stage. The edge is classified and colour coded according to the significant of motif count enrichment.

794 Motif count enrichment for TFs network: Initially footprints for each AML subtype were identified by using the Wellington algorithm<sup>29</sup> and were annotated to their related promoter 795 796 using CHi-C data where possible. Motif search within footprint coordinates where performed 797 using HOMER<sup>61</sup>. The number of motifs per TF gene were counted and the significance of 798 motif enrichment was identified using bootstrapping on random sampling, a random set of 799 mapped motif were extracted from all union footprinted motif of all AML subtypes and the 800 CD34+ cells. After 1000 iterations the mean, standard deviation and the z-scores are 801 computed. Motif  $(TF_a)$  is linked to gene  $(TF_b)$  with only positive Z-score.

802 *Motif count enrichment for up-regulated TFs:* The correlations (r<sub>e</sub>) between all TF genes 803 based on FPKM values from the RNA-seq analysis were identified and the correlations (r<sub>m</sub>) 804 between all TF genes based on motif count binding were identified. The correlation 805 coefficients were z-transformed using Fisher Z-transformation with "FisherZ" function in R. 806 The average of the transformed z-scores of both gene expression and motif were 807 transformed to correlation (r). All TF genes with a correlation coefficient equal or greater 808 than a cut-off of 0.3 were considered. Then for each AML cell type, the differentially 809 expressed TF genes among these correlated genes were identified. First with AML subtype 810 as compared to CD34+ cells and second with AML subtype compared to the average 811 expression of other subtypes includes the CD34+. Up-regulated genes with a 2-fold-change 812 in expression were either compared to CD34+ or compared to other AMLs were considered

- 813 to construct the network. Motif enrichment for the correlated and up-regulated TF genes and
- 814 edges were identified as described above.
- 815 *List of used position weight matrices:* A description of how the motifs were curated can
- be found in the legend of Table S2.
- 817

#### 818 **Data availability**

- 819 Processed data will be available from our webserver
- 820 <u>http://bioinformatics-bham.co.uk/tfinaml/</u>
- 821 Password sal2018.
- 822 Raw data have been deposited at GEO under the accession number GSE108316.
- 823

#### 824 References

- Cancer Genome Atlas Research, N. Genomic and epigenomic landscapes of adult
   de novo acute myeloid leukemia. *N Engl J Med* 368, 2059-74 (2013).
- 827 2. Papaemmanuil, E. *et al.* Genomic Classification and Prognosis in Acute Myeloid
- Eukemia. *New England Journal of Medicine* **374**, 2209-2221 (2016).
- 829 3. Bonifer, C. & Cockerill, P.N. Chromatin Structure Profiling Identifies Crucial
  830 Regulators of Tumor Maintenance. *Trends Cancer* 1, 157-160 (2015).
- 831 4. Rosenbauer, F. & Tenen, D.G. Transcription factors in myeloid development:
  832 balancing differentiation with transformation. *Nature reviews. Immunology* 7, 105-17
  833 (2007).
- S. Cockerill, P.N. Receptor Signaling Directs Global Recruitment of Pre-existing
  Transcription Factors to Inducible Elements. *Yale J Biol Med* **89**, 591-596 (2016).
- 836 6. Ward, A.F., Braun, B.S. & Shannon, K.M. Targeting oncogenic Ras signaling in
- hematologic malignancies. *Blood* **120**, 3397-406 (2012).

- 838 7. Parikh, C., Subrahmanyam, R. & Ren, R. Oncogenic NRAS rapidly and efficiently
  839 induces CMML- and AML-like diseases in mice. *Blood* 108, 2349-57 (2006).
- 840 8. Masson, K. & Ronnstrand, L. Oncogenic signaling from the hematopoietic growth
  841 factor receptors c-Kit and Flt3. *Cell Signal* 21, 1717-26 (2009).
- 842 9. Gerloff, D. *et al.* NF-kappaB/STAT5/miR-155 network targets PU.1 in FLT3-ITD843 driven acute myeloid leukemia. *Leukemia* 29, 535-47 (2015).
- 84410.Corces-Zimmerman, M.R., Hong, W.J., Weissman, I.L., Medeiros, B.C. & Majeti, R.845Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators
- and persist in remission. *Proc Natl Acad Sci U S A* **111**, 2548-53 (2014).
- 847 11. Shlush, L.I. *et al.* Identification of pre-leukaemic haematopoietic stem cells in acute
  848 leukaemia. *Nature* 506, 328-33 (2014).
- B49 12. Di Croce, L. & Helin, K. Transcriptional regulation by Polycomb group proteins.
  Nature structural & molecular biology 20, 1147-55 (2013).
- Broske, A.M. *et al.* DNA methylation protects hematopoietic stem cell multipotency
  from myeloerythroid restriction. *Nature genetics* **41**, 1207-15 (2009).
- 853 14. Bonifer, C. & Bowen, D.T. Epigenetic mechanisms regulating normal and malignant
  haematopoiesis: new therapeutic targets for clinical medicine. *Expert reviews in molecular medicine* 12, e6 (2010).
- 856 15. Challen, G.A. *et al.* Dnmt3a is essential for hematopoietic stem cell differentiation.
  857 *Nature genetics* 44, 23-31 (2012).
- 16. Ko, M. *et al.* Impaired hydroxylation of 5-methylcytosine in myeloid cancers with
  mutant TET2. *Nature* 468, 839-43 (2010).
- Shih, A.H., Abdel-Wahab, O., Patel, J.P. & Levine, R.L. The role of mutations in
  epigenetic regulators in myeloid malignancies. *Nature reviews. Cancer* 12, 599-612
  (2012).

- 863 18. Goode, D.K. *et al.* Dynamic Gene Regulatory Networks Drive Hematopoietic
  864 Specification and Differentiation. *Dev Cell* 36, 572-87 (2016).
- 865 19. Obier, N. & Bonifer, C. Chromatin programming by developmentally regulated
  866 transcription factors: lessons from the study of haematopoietic stem cell specification
  867 and differentiation. *FEBS Lett* **590**, 4105-4115 (2016).
- Wilson, N.K. *et al.* Combinatorial transcriptional control in blood stem/progenitor
  cells: genome-wide analysis of ten major transcriptional regulators. *Cell Stem Cell* 7,
  532-44 (2010).
- Rubin, A.J. *et al.* Lineage-specific dynamic and pre-established enhancer-promoter
  contacts cooperate in terminal differentiation. *Nat Genet* 49, 1522-1528 (2017).
- Ptasinska, A. *et al.* Identification of a Dynamic Core Transcriptional Network in
  t(8;21) AML that Regulates Differentiation Block and Self-Renewal. *Cell Reports* 8,
  1974-1988 (2014).
- 876 23. Loke, J. *et al.* RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the
  877 Chromatin Landscape in t(8;21) and t(3;21) AML. *Cell Rep* 19, 1654-1668 (2017).
- 878 24. Cauchy, P. *et al.* Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is
  879 Connected to a Specific Chromatin Signature. *Cell Rep* 12, 821-36 (2015).
- 880 25. Corces, M.R. *et al.* Lineage-specific and single-cell chromatin accessibility charts
  881 human hematopoiesis and leukemia evolution. *Nat Genet* 48, 1193-203 (2016).
- McKeown, M.R. *et al.* Superenhancer Analysis Defines Novel Epigenomic Subtypes
  of Non-APL AML, Including an RARalpha Dependency Targetable by SY-1425, a
  Potent and Selective RARalpha Agonist. *Cancer Discov* 7, 1136-1153 (2017).
- 885 27. Martens, J.H. *et al.* ERG and FLI1 binding sites demarcate targets for aberrant
  886 epigenetic regulation by AML1-ETO in acute myeloid leukemia. *Blood* 120, 4038-48
  887 (2012).

- Pulikkan, J.A., Tenen, D.G. & Behre, G. C/EBPalpha deregulation as a paradigm for
  leukemogenesis. *Leukemia* 31, 2279-2285 (2017).
- 890 29. Piper, J. *et al.* Wellington: a novel method for the accurate identification of digital
  891 genomic footprints from DNase-seq data. *Nucleic Acids Res* **41**, e201 (2013).
- 892 30. Ptasinska, A. *et al.* Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome893 wide changes in chromatin structure and transcription factor binding. *Leukemia* 26,
  894 1829-1841 (2012).
- Mandoli, A. *et al.* CBFB-MYH11/RUNX1 together with a compendium of
  hematopoietic regulators, chromatin modifiers and basal transcription factors
  occupies self-renewal genes in inv(16) acute myeloid leukemia. *Leukemia* 28, 770-8
  (2014).
- Bunne, J. *et al.* AML1/ETO proteins control POU4F1/BRN3A expression and function
  in t(8;21) acute myeloid leukemia. *Cancer Res* **70**, 3985-95 (2010).
- 33. Dekker, J., Rippe, K., Dekker, M. & Kleckner, N. Capturing chromosome
  conformation. *Science* 295, 1306-11 (2002).
- 903 34. Mifsud, B. *et al.* Mapping long-range promoter contacts in human cells with high-904 resolution capture Hi-C. *Nat Genet* **47**, 598-606 (2015).
- 905 35. Chasman, D. & Roy, S. Inference of cell type specific regulatory networks on
  906 mammalian lineages. *Curr Opin Syst Biol* 2, 130-139 (2017).
- 907 36. Neph, S. *et al.* Circuitry and dynamics of human transcription factor regulatory
  908 networks. *Cell* **150**, 1274-86 (2012).
- 909 37. Lin, S. *et al.* A FOXO1-induced oncogenic network defines the AML1-ETO
  910 preleukemic program. *Blood* 130, 1213-1222 (2017).
- 911 38. O'Connor, C. *et al.* Nfix expression critically modulates early B lymphopoiesis and
  912 myelopoiesis. *PLoS One* **10**, e0120102 (2015).

- 913 39. Somerville, T.D. *et al.* Frequent Derepression of the Mesenchymal Transcription
  914 Factor Gene FOXC1 in Acute Myeloid Leukemia. *Cancer Cell* 28, 329-42 (2015).
- 915 40. Olive, M. *et al.* A dominant negative to activation protein-1 (AP1) that abolishes DNA
  916 binding and inhibits oncogenesis. *J Biol Chem* 272, 18586-94 (1997).
- 917 41. Obier, N. *et al.* Cooperative binding of AP-1 and TEAD4 modulates the balance
  918 between vascular smooth muscle and hemogenic cell fate. *Development* 143, 4324919 4340 (2016).
- 920 42. Verhaak, R.G.W. *et al.* Prediction of molecular subtypes in acute myeloid leukemia
  921 based on gene expression profiling. *Haematologica* 94, 131-134 (2009).
- 922 43. Figueroa, M.E. *et al.* DNA Methylation Signatures Identify Biologically Distinct
  923 Subtypes in Acute Myeloid Leukemia. *Cancer cell* **17**, 13-27 (2010).
- 44. Lin, S., Mulloy, J.C. & Goyama, S. RUNX1-ETO Leukemia. *Adv Exp Med Biol* 962,
  151-173 (2017).
- 926 45. Goyama, S. *et al.* UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human
  927 preleukemia induced by AML1-ETO. *Leukemia* **30**, 728-39 (2016).
- 928 46. Sun, X.J. *et al.* A stable transcription factor complex nucleated by oligomeric AML1929 ETO controls leukaemogenesis. *Nature* **500**, 93-7 (2013).
- 47. Essig, A., Duque-Afonso, J., Schwemmers, S., Pahl, H.L. & Lubbert, M. The
  AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic
  precursor cells. *Leuk Res* 38, 340-5 (2014).
- 933 48. Trop-Steinberg, S. & Azar, Y. AP-1 Expression and its Clinical Relevance in Immune
  934 Disorders and Cancer. *Am J Med Sci* 353, 474-483 (2017).
- 49. Kesarwani, M. *et al.* Targeting c-FOS and DUSP1 abrogates intrinsic resistance to
  tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. *Nat Med* 23, 472482 (2017).

- 938 50. Faber, Z.J. *et al.* The genomic landscape of core-binding factor acute myeloid
  939 leukemias. *Nat Genet* 48, 1551-1556 (2016).
- 51. Levis, M. *et al.* Results from a randomized trial of salvage chemotherapy followed by
  lestaurtinib for patients with FLT3 mutant AML in first relapse. *Blood* **117**, 3294-301
  (2011).
- 943 52. DePristo, M.A. *et al.* A framework for variation discovery and genotyping using next-944 generation DNA sequencing data. *Nat Genet* **43**, 491-8 (2011).
- 945 53. van Gosliga, D. *et al.* Establishing long-term cultures with self-renewing acute
  946 myeloid leukemia stem/progenitor cells. *Exp Hematol* **35**, 1538-49 (2007).
- 947 54. Weber, K., Bartsch, U., Stocking, C. & Fehse, B. A multicolor panel of novel lentiviral
  948 "gene ontology" (LeGO) vectors for functional gene analysis. *Mol Ther* 16, 698-706
  949 (2008).
- 950 55. Mostoslavsky, G. *et al.* Efficiency of transduction of highly purified murine
  951 hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of
  952 minimal in vitro manipulation. *Mol Ther* **11**, 932-40 (2005).
- 953 56. Bert, A.G., Johnson, B.V., Baxter, E.W. & Cockerill, P.N. A modular enhancer is
  954 differentially regulated by GATA and NFAT elements that direct different tissue955 specific patterns of nucleosome positioning and inducible chromatin remodeling. *Mol*956 *Cell Biol* 27, 2870-85 (2007).
- 957 57. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat*958 *Methods* 9, 357-9 (2012).
- 959 58. Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol* 9, R137
  960 (2008).
- 961 59. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and
  962 dispersion for RNA-seq data with DESeq2. *Genome Biol* 15, 550 (2014).

- 60. Kumar, V. *et al.* Uniform, optimal signal processing of mapped deep-sequencing
  data. *Nat Biotechnol* **31**, 615-22 (2013).
- 965 61. Heinz, S. *et al.* Simple Combinations of Lineage-Determining Transcription Factors
  966 Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities.
  967 *Molecular Cell* 38, 576-589 (2010).
- 968 62. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15-21
  969 (2013).
- 970 63. Trapnell, C. *et al.* Differential analysis of gene regulation at transcript resolution with
  971 RNA-seq. *Nat Biotechnol* **31**, 46-53 (2013).
- 972 64. Ritchie, M.E. *et al.* limma powers differential expression analyses for RNA-973 sequencing and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).
- 974 65. Bindea, G. *et al.* ClueGO: a Cytoscape plug-in to decipher functionally grouped gene
  975 ontology and pathway annotation networks. *Bioinformatics* 25, 1091-3 (2009).
- 976 66. Segal, E., Friedman, N., Koller, D. & Regev, A. A module map showing conditional
  977 activity of expression modules in cancer. *Nat Genet* **36**, 1090-8 (2004).
- 978 67. Wingett, S. *et al.* HiCUP: pipeline for mapping and processing Hi-C data. *F1000Res*979 4, 1310 (2015).
- 980 68. Mifsud, B. *et al.* GOTHiC, a probabilistic model to resolve complex biases and to 981 identify real interactions in Hi-C data. *PLoS One* **12**, e0174744 (2017).
- 982 69. Zhang, H.M. *et al.* AnimalTFDB: a comprehensive animal transcription factor
  983 database. *Nucleic Acids Res* 40, D144-9 (2012).

985

986

## 987 Acknowledgements

- 988 This research was funded by a programme grant from Bloodwise (15001) to C.B. and P.N.C,
- 989 as well as studentship awards from Cancer Research UK and Bloodwise to A.Pickin and
- 990 N.G, respectively, a Kay Kendall Clinical Training Fellowship for J.L. and a MRC/Leuka
- 991 Clinical Training Fellowship for S.P.
- 992

993

## 994 Author Affiliations

- <sup>995</sup> <sup>1</sup> Institute of Cancer and Genomic Sciences, University of Birmingham, B17 2TT, UK
- <sup>996</sup> <sup>2</sup>Northern Institute for Cancer Research, University of Newcastle, Newcastle, UK
- <sup>997</sup> <sup>3</sup>Section of Experimental Haematology, Leeds Institute for Molecular Medicine, University of
- 998 Leeds, Leeds LS9 7TF, UK
- 999 <sup>4</sup> West Midlands Regional Genetics Laboratory, Birmingham Women's NHS Foundation
- 1000 Trust, Birmingham B15 2TG, UK
- <sup>5</sup>CMT Laboratory NHS Blood & Transplant, Edgbaston, Birmingham, B15 2SG, UK
- <sup>6</sup> Department of Hematology, Erasmus University Medical Center, Dr. Molewaterplein 50,
- 1003 3015 GE Rotterdam, the Netherlands
- <sup>7</sup> Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds LS9
- 1005 7TF, UK
- <sup>8</sup>Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham B15 2TG, UK, UK

1007

## 1008 Author contributions:

- M.R.I., D.C., S.P., A.P, H.P., A. Pickin, N.G., J.L., P.S.C, R.R., S.R.J. performed
  experiments and generated data, H.R.D., M.R., S.R., M.G. P.J., A.U. provided patient
  samples, S.C., A,B, and P.N.C. conducted mutation analysis, S.A.A. and P.C. analysed
  data, O.H. supervised transplantation experiments and helped editing the manuscript, C.B.
  and P.N.C. conceived and directed the study and CB wrote the manuscript.
- 1014

## 1015 **Competing financial interests**

- 1016 The authors declare no competing financial interests.
- 1017

## 1018 **Corresponding authors**

- 1019 Constanze Bonifer (c.bonifer@bham.ac.uk) and Peter N. Cockerill
- 1020 (p.n.cockerill@bham.ac.uk).
- 1021

1022 Figure Legends

1023

Figure 1: Different types of AML adopt unique transcriptome and chromatin landscapes. (A) Experimental strategy. (B) UCSC Genome browser tracks of DNasel-seq mapping in purified AML cells. (C) Hierarchical clustering of Pearson correlation coefficients of DNasel accessible sequences from all patient samples with normalized read counts of DNasel-Seq data for the different classes of mutations (left panel), right panel: list of mutations in cells from each patient

1030

1031

1032 Figure 2: Different types of AML are blocked at different stages of differentiation and 1033 are regulated by different transcriptional network. (A) Hematopoietic hierarchy; shown 1034 are some of the precursor stages from which ATAC-seq and RNA-seq data were generated 1035 in Corces et al., 2016: Hematopoietic stem cells (HSC), common myeloid progenitors 1036 (CMP), common lymphoid progenitors (CLP), Megakaryocyte Erythrocyte Precursors (MEP) 1037 and Granulocyte Macrophage Precursors (GMP). (B) Clustering of the correlation of 1038 percentage of peak overlap between DNasel-Seg and ATAC-seg data by first generating a 1039 matrix with all overlap percentages between all DHS peaks, and ATAC-seg peaks and then 1040 hierarchically clustering. (C) Gene set enrichment analysis for the differentially expressed 1041 genes that are at least 2-fold different compared to the normal CD34+ PBSCs. Up and down 1042 regulated gene expression patterns were tested for their similarity to specific pairs of 1043 progenitor RNA-seq data from Corces et al. 2016, representing different steps of 1044 differentiation. Up-regulated genes are shown in top panel and the bottom panel shows the 1045 down-regulated genes.

1046

1047

1048 Figure 3: AML-specifically active cis-regulatory elements cluster into common and 1049 unique chromatin landscapes. (A) Heatmap depicting unsupervised K-mean clustering of 1050 the DNasel-Seg log2 signals seen in each AML specific distal DHS peak in each AML 1051 sample compared to PBSCs. Clustering was done only on rows (DHS peaks) while samples 1052 were ranked based on the clustering in Figure 1C. A diagram on top of the heatmap shows 1053 the DHS peak population used for clustering. (B) A binary heatmap shows the overlap 1054 between the clusters from A and the DHSs of the 7 mutation classes which are deregulated 1055 compared to CD34+ve PBSCs as described in Fig S4A. (C) The percentage of DHS peaks 1056 that overlap with ATAC-Seg data from different progenitor types, DHS clusters from Figure 1057 3A was overlapped with each of the progenitor ATAC peaks; these include CLP, CMP, 1058 GMP, MPP, LMPP, MEP and Monocyte populations.

1059

1060 Figure 4: AML-specifically active cis-regulatory elements display AML type-specific 1061 transcription factor occupancy patterns. (A) UCSC browser screen shot of the MDFI 1062 locus zooming in on an AML type-specific DHS (box). (B) Heatmap depicting the degree of 1063 motif enrichment after hierarchical clustering of motif occupancy in each of the 20 AML DHS 1064 clusters. Enrichment score was calculated by the level of motif enrichment in all the 1065 footprints of all high read-depth samples for each cluster, as compared to union of footprints 1066 in all experiments. (C) Enrichment analysis of motifs footprinted in AML subgroups which 1067 overlap with ATAC-Seq peaks present in precursor cells<sup>25</sup>.

1068

Figure 5: Capture HiC shows differences in locus-specific cis-regulatory interactions between different types of AML and normal cells. (A) Heatmaps showing the raw interactions of the promoter capture HiC data using purified patient blasts on chromosome 2 for the FLT3-ITD (FLT3-ITD/NPM1 patient) (left), t(8;21) (middle) and CD34+ (right), a UCSC tracks is shown below each heatmap. (B) Flow diagram shows the step for

1074 identification of the differential interactions and the downstream analysis. (C) Percentage of 1075 up- and down-regulated genes with differential interactions from the FLT3-ITD and the 1076 t(8;21) compared to CD34<sup>+</sup>. The bar figure shows also the percentage of the common genes 1077 for the FLT3-ITD and the t(8;21), the number of DEG is shown on top of each bar. (D) Top 1078 enriched GO terms for the up-regulated genes of the FLT3-ITD compared to the CD34+ as 1079 outlined in (A). (E) Network diagram of top KEGG pathways for the up-regulated genes of 1080 the FLT3-ITD compared to the CD34+ as outlined in (A). (F) Top enriched GO terms for the 1081 up-regulated genes of the t(8;21) compared to the CD34+ shown as outlined in (A) Network 1082 diagram of top KEGG pathways for the up-regulated genes of the t(8:21) compared to the 1083 CD34+ as outlined in (B). (H): percentage of RUNX1-ETO and RUNX1 targets amongst up-1084 regulated genes with differential interactions.

1085

# Figure 6: Identification of transcription factor networks driving the expression of AML type-specific up-regulated TF genes

1088 (A) Outline of analysis strategy. (B) t(8;21)-specific TF network, (C) CEBPA(x2)-specific TF,

1089 (D) INv(16) specific TF network, (E) Mutant RUNX1-specific TF network, (F) FLT3-1090 ITD/NPM1 specific TF network, (G) NPM1-specific TF network


1091 Factor families binding to the same motif as shown in Table S2 form a node contained within 1092 a circle. Arrows going outwards from the entire node highlight footprinted motifs in individual 1093 genes generated by any member of this factor family whereby the footprint was annotated to 1094 the gene using the CHiC data where possible, otherwise to the nearest gene. For selected 1095 nodes, the name of the underlying motif is highlighted in large grey letters. The expression 1096 level (FKPM) for the individual genes is depicted in white (low)/red (high) colour. An orange 1097 smooth ring around the circle indicates that this gene is specifically up-regulated in this type 1098 of AML compared to CD34+ PBSCs and/or other AML types, a dotted circle indicates a gene that is up-regulated as compared to CD34+ cells. Genes with no outgoing arrows due to alack of know binding motifs are highlighted by their octagon shapes.

1101

# 1102 7: Identification of AML type-specific TFs required for maintaining leukemic growth1103 and colony forming ability.


1104 (A - C) Histogram showing the growth curves of (A) Kasumi-1 cells after transduction with 1105 shPOU4F1 and (B) of MV4-11 cells after transduction with shNFIX. (D, E) Histogram 1106 showing the number of colonies formed by a FLT3-ITD+ primary AML cell samples (D) or 1107 PBSCs (E) after transduction with shRNA targeting FOXC1, NFIX or a mismatch control. (F) 1108 Histogram showing the growth curve of Kasumi-1 cells transduced with either a doxycycline-1109 inducible dominant negative FOS or an empty vector control (right panel) with and without 1110 1.5 mcg/ml doxycycline. (G) Histogram showing the growth curve of MV4-11 cells 1111 transduced with either a doxycycline-inducible dominant negative FOS or an empty vector 1112 control (right panel) with and without 1.5 µg/ml doxycycline. (H,I) The expression of a 1113 dominant negative FOS causes a reduction in the colony forming ability of CD34<sup>+</sup> FLT3-ITD+ 1114 primary AML cells (H) but not CD34<sup>+</sup> PBSCs (I). All experiments were performed in triplicate 1115 (n=3) with \* p<0.05, \*\*p<0.01. Error bars show 95% confidence intervals. (J) (J) 1116 Granulosarcoma formation in RG mice by Kasumi-1 expressing a doxycycline-inducible 1117 dnFOS. dnFOS was induced by intraperitoneal injection of doxycycline. (K) Survival curve 1118 for RG mice transplanted with MV4-11 cells expressing doxycycline-inducible dnFOS. 1119 dnFOS was induced by adding doxycycline to the drinking water. The control group did not 1120 develop any tumors during the observed time frame while all mice of the induced group had 1121 to be sacrificed.

- 1122
- 1123
- 1124




## Figure 2


С




ATAC-Seq & RNA-Seq data from Corces et al., 2016


Gene set enrichment analysis






Similarity between AML DHSs and progenitor ATAC





Cluster ID


## Figure 4





## 

**Cluster ID** 

Motif









t(8;21) specific TF network


CEBPA(x2) specific TF network





Inv(16) specific TF network

Mutant RUNX1 specific TF network



NPM1 specific TF network

FLT3-ITD/NPM1 specific TF network





Figure 7



Long terminal repeat (LTR) elements are wide-spread in the human genome and have the 30 potential to act as promoters and enhancers. Their expression is therefore under tight 31 epigenetic control. We previously reported in classical Hodgkin Lymphoma (cHL) that a 32 member of the THE1B class of LTR elements acted as a promoter for the proto-oncogene 33 and growth factor receptor gene CSF1R and that expression of this gene is required for 34 cHL tumour survival. However, to which extent and how such elements participate in 35 globally shaping the unique cHL gene expression program is unknown. To address this 36 question we mapped the genome-wide activation of THE1-LTRs in cHL cells using a 37 targeted next generation sequencing approach (RACE-Seq). Integration of these data with 38 global gene expression data from cHL and control B cell lines showed a unique pattern of 39 LTR activation impacting on gene expression, including genes associated with the cHL 40 phenotype. We also show that global LTR activation is induced by strong inflammatory 41 stimuli. Together these results demonstrate that LTR activation provides an additional layer 42 of gene deregulation in classical Hodgkin lymphoma and highlight the potential impact of 43 genome-wide LTR activation in other inflammatory diseases.

## **Supplemental Materials**

## **1. Supplemental Figures and Tables**

**Supplemental Table 1: Patient groups, mutation data, and clinical data.** Patient codes depicted in color represent samples included in the seven major defined mutation groups, or which have either 2 FLT-ITD mutations or a mutation in either CBL or NRAS. This table also indicates samples where DHS-Seq and RNA-Seq data is either available (Y) or not available (N). Further details can be found in Supplemental data-set 1.

patient code	Signalling	NPM1	Chrom	RUNX	Other mutations	DHS Seq		Age	Sex	wbc	case
ITD-1	FLT3-ITD DNMT3A, TET2x2, BCOR, TP53		Y	Y	45	F	56	Rel			
ITD-2	FLT3-ITD		tri(13)		DNMT3A, TET2	Y	Y	68	F	2	Pres
ITD-3	FLT3-ITD				DNMT3A	Y	Y	80	F	143	Pres
ITD/NMP1-1	FLT3-ITD	NPM1			DNMT3A, WT1	Y	Y	45	F	32	Pres
ITD/NPM1-2	FLT3-ITD	NPM1				Y	Y	61	F	7	Rel
ITD/NPM1-3	FLT3-ITD	NPM1				Y	Y	66	F	91	Pres
ITD/NPM1-4	FLT3-ITD	NPM1			GATA2, DNMT3A	Y	Y	65	F	21	Pres
ITD/NPM1-5	FLT3-ITD	NPM1			DNMT3A, BCOR	Y	Y	68	М	190	Pres
ITD/NPM1-6	FLT3-ITD	NPM1			WT1, DNMT3A, TET2, PHF6	Y	Y	58	F	195	Pres
NPM1-1		NPM1			IDH1	Y	Y	37	М	60	Pres
NPM1-2		NPM1			DNMT3A, TET2x2	Y	Y	75	М	94	Pres
t(8;21)-1			t(8;21)		TET2	Y	Y	72	М	29	Pres
t(8;21)/KIT-2	KIT		t(8;21)		NOTCH1	Y	Y	48	М	36	Pres
t(8;21)-3	FLT3-TK		t(8;21)			Y	Y	53	М	6	Pres
t(8;21)-4			t(8;21)			Y	Y	45	М	2	Pres
inv(16)-1	KIT		inv(16)			Y	Y	40	М	22	Pres
inv(16)-2			inv(16)			Y	Y	26	М	63	Pres
inv(16)-3			inv(16)		ASXL1	Y	Y	75	М	54	Pres
RUNX1-DT-1	FLT3		tri(13)	RUNX1	CREBBP, DNMT3A, SF3B1	Y	Y	68	М	112	Rel
RUNX1-DT/CEBPA-2	FLT3-ITD		. ,	RUNX1	CEBPA, WT1x2, SF3B1, TP53	Y	Y	83	М	68	Pres
RUNX1-DT-3				RUNX1		Y	Y	58	М	37	Pres
RUNX1(x2)-D&T-4				RUNX1x2	SRSF2, DNMT3A, IDH2	Y	Y	82	М	55	Pres
RUNX1-D-5				RUNX1	IDH1, BCORL1x2, SRSF2x2	Y	Y	65	М	8	Pres
RUNX1-T/CEBPA-6	NRAS		tri (8)	RUNX1	CEBPA, EZH2	Y	Y	75	М	107	Pres
CEBPA(x2)-1	-		- (-)	-	CEBPAx2	Y	Y	76	F	238	Pres
CEBPA(x2)-2					CEBPAx2. GATA2	Y	Y	21	F	10	Pres
CEBPA(x2)-3					CEBPAx2, GATA2, TET2	Y	Y	75	М	106	Pres
ITD(2x)/NPM1-1	FLT3-ITDx2	NPM1			DNMT3A, IDH2	Y	Y	78	F	26	Pres
ITD(2x(/NPM1-2	FLT3-ITDx2	NPM1			CEBPA, IDH2	Y	Y	72	F	68	Pres
NPM1/RAS-3	NRAS	NPM1			PTPN11, DNMT3A, IDH1	Y	Y	30	F	4	Rel
inv(3)/RAS-3	NRAS		inv(3)		ETV6, SF3B1	N	Y	54	М	104	Pres
inv(3)/RAS-1	NRAS		inv(3)		GATA2, SF3B1	Y	Y	59	М	4	Rel
inv(3)/CBL-2	CBL		inv(3)		SF3B1	Y	N	34	F	21	Rel
t(8;21)/ITD(x2)-5	FLT3-ITD		t(8;21)		SMC1A	N	Y	43	М	86	Pres
RUNX1-D/JAK-1	JAK2		tri (21, 9)	RUNX1	IDH2, SRSF2	Y	Y	79	М	12	Pres
RUNX1-T/JAK-2	JAK2			RUNX1	TET2x2, TP53	Ý	Ŷ	77	F	79	Pres
RUNX1-T-7 (NHL)			tri (21)	RUNX1	TET2x2, PHF6	Ý	Ŷ	73	F	NA	Pres
CEBPA-5	1		(= . ,		CEBPA, DNMT3A	N	Ŷ	79	F	40	Pres
SRSF2-1	1				IDH2, SRSF2	N	Ŷ	67	M	2	Pres
SRSF2-2					SOCS1, DNMT3A, IDH2, SRSF2	N	Ŷ	71	M	2	Pres
t(8;21)-1R	KIT		t(8;21)		TET2	Y	Y	72	M	29	Rel

## Supplemental Table 2

motif	logo	motif	logo	motif	logo
AHR	<b>IGCGTG</b>	HSF1	<b>IICIAGAASETTCIE</b>	PRDM1	<b>SAAAGIGAAAGI</b>
AP-1	<b><b><u>ETGASTCA</u></b></b>	IKZF	<b>ETTCCCASE</b>	PU.1	
AR	<b>ACATE ICLES</b>	IRF	GAAASIGAAASI	RAR	
BCL6	ZASSITICCACCAAS	IRX	<b>ACTIACATGICA</b>	REST	<u>GGAGCTGTCCATGGTGCTGA</u>
CAMTA		KLF		RFX	<b><u>FEGTTECCATGGEAAC</u></b>
C/EBP	ATTGESCAAS	LEF1	<b>AGATCAAAGG</b>	RUNX	<b>EETGTGGTIT</b>
CREB/ATF	<b>SEGIGACGTCAS</b>	MAF	<b><u>GCTGASTCAGCA</u></b>	RXR	<b><u>TAGGGCAAAGGTCA</u></b>
CTCF	<b>TRACE ACTACATOC</b>	MYC/MAX	SCACGTG SE	SMAD	<mark>ଛ୍ଟ୍ଟ୍ସ୍ଟ୍ରେମ୍ପେମ୍ଭ୍</mark> ର୍୍
CUT	<b>ZECATCAAT</b>	MEF2	<b>TCTARAAATACS</b>	SNAI	<b>FESCACCTGCIE</b>
E2F	<b><u>TEGCCGEGAAA</u></b>	MEIS	ATCTGTCA	SOX	<b><u><u>SCITTGTIC</u></u></b>
EGR	<u><u><u>Eg</u>egtgtggge</u></u>	MITF	<b>SICAIGTGAC</b>	SP	<u>Seccesce</u>
ESR1	<u> <u>EAGGICASE</u>TGACCIE</u>	MNX1	물로TAAT	SRF	
ESRRA	<b>Ç<u>eaag</u>çıca</b> ş	MYB		ST18	ASAAAGTTTSS
ETS		NF1	<u> FETGGCAFTFIGCCAG</u>	STAT3	<b><u><u>STTCC</u>SGGAA</u></b>
ETS:E-box		NFAT		STAT5	<b>ATTCIAGAA</b>
EVI	FAGATAAGATAA	NFE2	TGCTGAGTCAC	STAT6	TTCCETAGAA
FOXO	SETGTTIACSES	NFIL3	<b>ÊTTAUGTAAJÊÊÊ</b>	TAL1	
FOX:E-box	TGTTIIIACAGCTG	NF-kB		TCF3	<b>EEECAGCTGE</b>
GATA	<b>EAGATAAGE</b>	NFY	<b>AGCCAATSAG</b>	TEAD	<del>द्विद्व<b>द्व</b>द्वद्वद्वद्वद्वद्वद्वद्वद्वद्वद्वद्वद्वद</del>
GFI1B	AAATCASIGC	NKX		TFCP2	
GLI	<u>⊊⊜TGGGTGGTC</u> ⊊	NR	<b>ECAAGGECA</b>	TFDP1	
HBP1		NRF1	<u><b>STGCGCATGCGC</b></u>	TGIF	<mark>ਣੂT<u>G</u>ACAG</mark> ਣੇ
HES	GECACGTGECEE	ост	<b>ZATG<u>C</u>AATSAS</b>	THR	<u>GGTCASSTGAGGTCA</u>
HHEX	<u> <u> ALTTAT</u></u>	PAX5	GTCACCETEEETGE	VDR	<u> ACACCTCATICACTICATAS</u>
HIC1	<b>TAGTICCACCETATA</b>	PBX	<b>ECATCAATCA</b>	VENTX	<b>SCATTA</b>
HIF1A	<mark>\$≣ACGTG</mark> ⊊	PKNOX1	<b>ESTGICASTCAS</b>	XBP1	
HINFP	IT SGTCCCC	POU4F1	<b>ATEAATPATTEA</b>		
НОХ	<b>SECATAAATCAT</b>	PPAR	T <u>CACCTTTCSCCCA</u>		


## List of used Position Weight Matrices

§

## Supplemental Table 2: List of representative position weight matrices for TF families.


To improve the process of linking regulatory factors with their binding sites on DNA, we consolidated the different versions of transcription factor consensus binding sequences for closely related family members where the motif signatures are indistinguishable. For most transcription factor families there are typically various alternate subtly different versions of position weight matrices for not just different family members but also for the same factor from different data sets. The prevalence of so many different related consensus sequences is a major impediment to the construction of regulatory networks from genome-wide analyses of DNA elements. For the current study, we first identified a subset of almost 300 transcription factor genes that are expressed in one or more of our AML samples. We then inspected the motifs listed on either the HOMER or JASPER databases, motifs defined in a recent large-scale study of recombinant proteins (Jolma et al 2013, 10.1016/j.cell.2012.12.009), or motifs described in various other publications. We grouped together those factors where the motifs are essentially the same, and chose the best representative example for further analysis. These selections were often validated by referring to the large body of literature which is devoted to defining specific motifs, which also informed the choices of which orientation of motifs represented the conventional form used in publications. The JASPAR motifs were viewed via http://jaspar.genereg.net/. The HOMER motifs were viewed via http://homer.ucsd.edu/homer/motif/HomerMotifDB/homerResults.html.

Supplementary Figure 1




**Supplemental Figure 1: Different types of AML adopt unique transcriptomes.** (A) Hierarchical clustering of gene expression as determined by RNA-Seq of all patient samples. Clustering of log2 FPKM values for all differentially expressed genes changing expression at least 2 fold in at least one patient as compared to normal CD34+ PBSC. (B) UCSC genome browser screenshots of DNasel-Seq in all AML patients with different classes of mutations and normal CD34+ PBSC at *POU4F1* (left panel) and *FOXC1* (right panel) locus. (C) Hierarchical clustering of Pearson correlation coefficient between all patient samples of RNA-Seq data: (left panel), right panel: list of mutations in cells from each patient. The correlation between any two patients was obtained with log2 FPKM expression values over all genes. (D) UCSC genome browser screenshots of RNA-Seq reads in AML patients at *POU4F1* (left panel) and *FOXC1* (right panel) locus. Asterisks denote samples for which the matching RNA-Seq or DNasel-Seq data are unavailable.

### **Supplementary Figure 2**



Supplemental Figure 2: Different types of AML adopt unique transcriptome and chromatinlandscapes. (A) Hierarchical clustering of Pearson correlation coefficients of DNasel


accessible sequences from all our patient samples with normalized read counts of DNase-Seq data for the different classes of mutations also including ATAC-Seg data from Corces et al., 2016 with similar mutations (SU(nnn), mostly FLT3-ITD). The mutation class is highlighted to the right of the panel and by a color code below the heatmap, again showing that specific elements from specific AML-types cluster together. Note the tight clustering of FLT3 and RAS mutant AML. (B) Scatter plots comparing the DNasel tag count signals of patients with (11) and without (8) DNMT3 mutations against each other and against PBSCs as indicated by colored shapes. (C) Smooth scatter plots showing the correlation between DNase-Seq and RNA-Seq data from AML patients. Shown are CD34+ PBSC cells from individual #1 versus individual #2 (left plot), CD34+ PBSC from individual #2 versus a patient with NPM1 and NRAS mutation (right plot). RNA-Seq plots (top panel) and DNasel-Seq plots (bottom panel). Other comparisons can be retrieved from the webserver. (D) Hierarchical clustering of log2 gene expression fold difference for all differentially transcription factor (TFs) and transcriptional regulator genes changing expression at least 2 fold in at least one patient as compared to normal CD34+ PBSC. Clustering was done only on rows (i.e., genes) while samples were ranked based on the clustering in Figure 1C. The heatmap colour is related to the degree of differential expression (fold-change (FC)). Red is up-regulated compared to normal CD34+ and blue is a down regulated TF.



Supplemental Figure 3: Different types of AML are blocked at different stages of differentiation and correlation with publicly available data-sets. (A) Smooth scatter plots show the correlation between AML DNase-Seq and ATAC-Seq data. Top panel shows the DNAsel-Seq from normal CD34+ PBSC patient #1 & #2 versus the ATAC-Seg from Hematopoietic stem cells (HSC) and lower panel shows the DNasel-Seq from normal CD34+ PBSC patient #1 & #2 versus the ATAC-Seg from Monocytes (Mono). (B) Hierarchical clustering of Pearson correlation coefficient between all patient samples of AML-Seg data plus the ATAC-seg data from Corces et al. The correlation between any two patients was obtained with normalized read counts calculated with +/- 200 bases from the peak center. (C) Gene set enrichment analysis for the up-regulated genes that are at least 2 fold difference compared to the normal CD34+. The AML up-regulated genes were tested for enrichment against the common myeloid progenitors (CMP) versus Granulocyte Macrophage Precursors (GMP) taken from Corces et al RNA-seq data. (D) Heatmap showing density enrichment of H3K27Ac peaks from McKeown et al., 2017 ranked according to the same coordinates of the DNase-Seq within the clusters (left heatmap), the H3K27Ac densities were plotted with a window size of +/- 2 kb around the DNasel-Seq peaks summit. Selected AMLspecific blocks of peaks are highlighted. The asterisk highlights samples inv(3)/CBL-2 for which RNA-Seg is available.

#### Α


Overlaps between mutation-specific upregulated DHSs





3085 ITD	DHSe								
			2228 IT	-	_	-	_	_	1
Motif	Match	%	Motif	Match	%	Motif	Mato		4
<b>EASACCAAST</b>	ETS	60	TGIGGILI	RUNX	62	IGTGGTIIS	RUN	_	4
<u> ZICFGCIII</u>	RUNX	54	<b>AASSGGAAS</b>		42	<b>SATGASTCA</b> I	AP-1		4
	E-box	34	<b>SOTGAOTCA</b>		24	<b>GFGTGGG</b>	EGR		4
SETGAETCAE	AP-1	23	AGGGAAATTCC	NF-kB	21	AAASAGGAAGTS	ETS	24	1
ICC State	NF1	20	TGCGTGGGAG	EGR	19	<b>XARZOSANI</b>	C/EE	3P 17	
<u>I</u> GCGTCGGAG	EGR	19	FSTTSFSSA	C/EBP	16				
AARESTTEE	C/EBP	14	_						
942 shared		M1	5366 t(8;2			5182 Inv(1		HSe	
Motif	Match	%	Motif	Match	%	Motif	Mate		1
TGIGGII	RUNX	70 54	AASAGGAAGT	ETS	62	CAASAGGAAGTS	ETS		
								-	-
AAGAGGAAGT	ETS	52	<b>SEEECACCTG</b>	E-box	47	*FICEGELLA	RUN		-
ATGASTCA	AP-1	24	<b>Şêtgastca</b> ł	AP-1	28	SETGACGICA	CRE		-
TGCGFSGGAG	EGR	18	TGIGGTIA	RUNX	26	<b>EOTGAOTCA</b>			4
TTÇÇÇÇAASS	C/EBP	16	TATTACCEA/	CEBP	19	ACAGCTGGET	E-bo		4
<u>GGGGATTICC</u>	NF-kB	10	GGGGAITICC	NF-kB	15	<b>STTOPSCAATSE</b>	C/EE	BP 12	
2004 05 05				4 0110-		¢ <u>ETITCAETTE</u>	IRF	7	
3961 CEBF			805 RUNX						
Motif	Match	%	Motif	Match	%				
CARAGAGGAAGI	ETS	51			66				
CATCICSE	E-box	46	SCACCTCCT		41				
IGIGGILISS	RUNX	45	<b>IGTGGTT</b>	RUNX	37				
<b>SOLOGICA</b>	AP-1	11	<b>ASTRASTCA</b>	AP-1	19	914 CEE	BPA.	Inv(16)	and
GGGGATTCCCS	NF-kB	10				t(8;21) s			
340 RUNX1	, Inv(16)	) and	390 CEB						
t(8;21) shar	ed DHS	s	RUNX1 s	1	1	Motif	<b>TTT</b>	Match	%
Motif	Match	%	Motif	Match	%	IGFGG		RUNX	53
<b>IGTGTTA</b>	RUNX	40	TGTGGT	RUNX	70	SAAASAG	_	ETS	49
CAGETGEE	E-box	45	SCASCT	C E-box	45	<b>TTGÇÇ</b>		C/EBP	33
AASAGGAAGT	ETS	24	AAGAGGAA	ETS	39	TOTE	ICAN	AP-1	28
<b>ACTGASTCA</b>	AP-1	9	ATGAST	A AP-1	15	SATGAC	TCA	CREB	27
			~						
			200 150 150 100 50 0	) - ) - ) -	•	•	•	•	300
			50 0	0	D POL	Nasel/tag o	coun 20 k	nt	
			- 50 0	0	D POL	Nasel/tag o	coun 20 k	nt K <b>b</b>	
			50 0	0	D POL	Nasel/tag o	coun 20 k	nt K <b>b</b>	
			- 50 0 300 250	• t(8;21)	D POL	Nasel/tag o	coun 20 k	nt K <b>b</b>	
			- 50 0 300 250	• t(8;21)	D POL	Nasel/tag o	coun 20 k	nt K <b>b</b>	
			- 50 0 300 250	• t(8;21)	D POL	Nasel/tag o	coun 20 k	nt K <b>b</b>	
			- 50 0 300 250	• t(8;21)	D POL	Nasel/tag o	coun 20 k	nt K <b>b</b>	
			- 50 0 300 250	• t(8;21)	D POL	Nasel/tag o	coun 20 k	nt K <b>b</b>	
			50 300 250 150 100	• t(8;21)	D POL	Nasel/tag o	coun 20 k	nt K <b>b</b>	
			- 50 0 300 250	• t(8;21)	D POL	Nasel/tag o	coun 20 k	nt K <b>b</b>	
			50 300 250 150 100	• t(8;21)	D POL	Nasel/tag o	coun 20 k	nt K <b>b</b>	
			50 300 250 200 150 150 300 250 200 200 300 250 200 250 200 200 200 200 200 200 2	• t(8;21)	POL & CE	Nasel/tag ( J4F1 + 2: BPAx2	coun 20 k	nt K <b>b</b>	
			50 300 250 200 150 150 300 250 200 200 300 250 200 250 200 200 200 200 200 200 2	• t(8;21)	POL & CE	Nasel/tag of J4F1 + 2: EBPAx2	<b>20 k</b> <b>•</b> Of <b>•</b> 400	nt ther AN	1L
			50 300 250 150 50 0	• t(8:21)		Nasel/tag o J4F1 + 2: EBPAx2 * * * * * * * * * * * * * * * * *	<b>20 k</b> <b>•</b> Of <b>•</b> 400	nt Kb ther AN	∩L 600
			50 300 250 Wy 200 150 150 50 0 0	t(8;21)	POU & CE	Nasel/tag o J4F1 + 2: EBPAx2 • • • • • • • • • • • • • • • • • • •	<b>20 k</b> <b>•</b> Of <b>•</b> 400	t t t t	∩L 600
	S	RS	50 300 250 Wydybee 150 150 50 0 1X1/JAK	• t(8:21)	POU & CE	Nasel/tag o J4F1 + 2: EBPAx2 • • • • • • • • • • • • • • • • • • •	<b>20 k</b> <b>•</b> Of <b>•</b> 400	t t t(8;2	600 <b>PA</b> 1)
	s		50 300 250 Wydybeservia 150 50 0 0 VX1/JAK SF2 3)	• t(8:21)	POL & CE 2 D (2 PM1 D/N	Nasel/tag o J4F1 + 2: EBPAx2 * * * * * * * * * * * * * * * * * * *	<b>20 k</b> • Of •	t t t(8;2 inv(1	600 <b>PA</b> 1)

NPM1/RAS

PBSC








ETS2

Supplemental Figure 4: AML-specifically active cis-regulatory elements cluster into common and unique chromatin landscapes and correlate with the upregulation of expression of the nearest genes. (A) Venn diagrams depicting the overlaps of subsets of DHSs which are up regulated compared to CD34+ve PBSCs within each of 7 mutation classes. These groups were generated as the average log2 values for 7 distinct subsets of AMLs that carried the same specific mutations in key regulators. These 7 mutation groups are defined on the basis of average values derived from 3 ITD patients, 6 ITD/NPM1 patients, 2 NPM1 patients, 4 t(8:21) patients, 3 inv(16) patients, 6 RUNX1 patients, and 3 patients with 2 CEBPA mutations. These groups are defined in Table S1 (note colour code). Up-regulated DHSs are defined as being at least 3-fold greater than in PBSCs, and have a DHS signal spanning a 400 bp window of at least 64. (B De novo motif search results using Homer for the up regulated DHSs classes and in overlapping deregulated DHSs for ITD and/or NPM1 and for CEBPA and RUNX1 that are shown in (A) the numbers indicate of percentage of each subset that contains the identified motif. (C) Gene set enrichment analysis for all expressed genes that are annotated to the DHSs identified in each of the AML specific 20 clusters, the enrichment scores (right panel) are aligned against each of the 20 clusters (left panel) that was initially described in Figure 3A. The target genes were tested for enrichment against all AML RNA-seg data; red color indicates that these genes are enriched with up-regulated genes compared to CD34+ PBSC. (D) Correlation of gene expression with DNasel tag count as exemplified for the POU4F1 gene (see also S1 B,D). (E) Bar figures depicting the expression level for some of the targets differentially expressed genes, the FPKM values were plotted on the y-axis for each AML samples used in this study, the color code identified each of the mutation classes.


#### Supplementary Figure 5



Validation of gene expression patterns (data from Verhaak et al)


Supplemental Figure 5: Common and group-specific DHS associate with genes belonging to different functional groups. Boxplots validating gene expression patterns for some of the differentially expressed genes genes using gene expression data from Verhaak et al (2009). P-

values highlighting the significance of differences are shown on each panel; the t-test was used to calculate the p-values.




**Supplemental Figure 6: AML-specifically active cis-regulatory elements are characterized by specific transcription factor binding patterns.** (A) Percentage of the footprints in the AML specific DHSs for the 20 clusters identified in Figure 3A. The footprints were identified using the Wellington algorithm. We first identified differential footprints for each AML sample compared to the CD34+ PBSCs and then the percentage of these differential footprints in the DHS subsets in the 20 clusters was calculated. (B) UCSC genome browser screenshot of DNAseI-Seq data aligned with digital footprints at the *C3AE1* locus. The screenshot shows the DHSs for one patient from each group. Footprint probabilities as calculated by Wellington (Piper et al., 2015) are indicated as grey density below the lines. The bottom indicates the precise location of occupied RUNX, C/EBP and AP-1 footprints. (C) Percentage of footprints with RUNX motifs in the indicated AML-types peaks which are bound by RUNX1 or RUNX1-ETO in ChIP assays from <sup>22,33,66</sup>. (D) Heatmap depicting the degree of motif enrichment after hierarchical clustering of all (not just the specific) motif enrichments for each of the mutation-specific AML groups. Enrichment scores were calculated by the level of motif enrichment in all the footprints of all Hi-read depth samples for each group, as compared to the union of footprints in all experiments.

#### Supplementary Figure 7




Supplemental Figure 7: Capture HiC shows differences in cis-regulatory interactions between different types of AML and normal cells. (A) Smooth scatter plots show the correlation

between t(8;21)-1 presentation and t(8;21)-1 relapse AML DNAsel-Seq data. (B) Heatmaps show the raw overall inter and intra interactions of the promoter capture HiC data for all chromosomes for FLT3-ITD (ITD/NPM1-2, left), t(8;21) (middle) and CD34+ (right) across all chromosomes. (C) Bar figure showing the percentage of DHSs within each of the 20 clusters identified in Figure 3A that have differential interactions compared to CD34+, (D, E) percentage of DHSs within each of the 20 clusters interacting with the nearest gene within differential interactions for all genes expressed genes as identified by the RNA-Seg data. D: FLT3-ITD and E: t(8:21). (F) Heatmap of differential interactions ranked by the strength of interaction (-log p-value) from highly significant to less for the FLT3-ITD and from less significant to more significant for the t(8:21) (left panel) Plotted along-side are the gene expression fold-difference for the FLT3-ITD compared to the t(8;21) and for the FLT3-ITD (middle panel) and the DHS fold difference FLT3-ITD versus the t(8;21) (right panel). (F) The top enriched GO terms for the up regulated genes in the FLT3-ITD compared the t(8:21) where the DHSs differentially interact with the promoter of that gene. Similarly the bottom panel the top enriched GO terms for the up regulated genes in the t(8;21) compared to the FLT3-ITD such that the DHS is differentially interact with the promoter of that gene.. (G) UCSC genome browser showing a screenshot of KLF2. The top two tracks display the log p-value of the capture HiC interaction for KLF2 promoter as viewpoint, the following two tracks display log p-value of the differential interaction of the t(8;21) and the FLT3-ITD compared to the CD34+. Shown are also the DNasel-Seq and RNA-Seq data of t(8;21), FLT3-ITD and CD34+ PBSC. (H) Bar diagram showing the percentage of DHSs involved in significant interactions. (I) Bar diagram showing the percentage of DHSs involved in significant differential interactions compared to CD34+ cells. (J) Bar diagram showing the percentage of DHSs involved in significant differential interactions for DHSs unique to FLT3-ITD or t(8;21) DHSs compared to CD34+ cells, with DHS common to FLT3-ITD and t(8;21) being excluded. (K) Enriched footprinted motifs in DHS associated each of the 20 clusters involved in differential interactions for the two patients. Motifs for transcription factors normally not expressed in myeloid cells are highlighted in yellow, motifs for inducible factors are marked in green.




## Supplemental Figure 8: Interactions are representative for their patient groups and the majority of interactions are shared (A)


(A) Percentage of all DHSs with interactions present in each dataset of each individual patients, (B) Heat-map highlighting the percentage of AML-type specific DHS with interactions found in the different patient groups, indicating that the patient chosen for the Chi-C experiment are representative for each patient group. (C) Percentage of up-regulated gens associated with DHS clusters that have significant interactions in any of the three Chi-C experiments. (D) Overlap of all DHSs underlying interactions in all three samples as indicated demonstrating that the majority of interactions are the same in all three samples.




VENT



t(8;21) TF network projected on CD34+ network




CEBPA(x2) TF network projected on CD34+ network





Mutant RUNX1 TF network projected on CD34+ network




FT3-ITD/NPM1 TF network projected on CD34+ network

NPM1 TF network projected on CD34+ network

Supplemental Figure 9: Identification of transcription factor network components driving the expression of TF genes in each AML subtype which are shared with CD34+ cells. Here we projected the links from the indicated AML subtypes onto the CD34+ footprints. Top panels: Analysis strategy. (A) Shared t(8;21) TF network, (B) Shared CEBPA(x2) TF, (C) Shared Inv(16) TF network, (D) Shared Mutant RUNX1 TF network, E) Shared FLT3-ITD/NPM1 TF network, (F) Shared NPM1- TF network. Factor families binding to the same motif as shown in Table S2 form a

node contained within a circle. Arrows going outwards from the entire node highlight footprinted motifs in individual genes generated by any member of this factor family whereby the footprint was annotated to the gene using the Chi-C data where possible, otherwise to the nearest gene. The expression level (FKPM) for the individual genes is depicted in white (low)/red (high) colour. An orange smooth ring around the circle indicates that this gene is specifically up-regulated in this type of AML compared to CD34+ PBSCs and/or other AML types, a dotted circle indicates a gene that is up-regulated as compared to CD34+ cells. Genes with no outgoing arrows due to a lack of know binding motifs are highlighted by an octagon shape. For a detailed guide to node and edge attributes: See legend of Figure 6.



## **Supplemental Figure 10**

**AML type-specifically expressed transcription factors are required for leukemic growth.** (A, B, C) Histograms showing *POU4F1* (A), *FOXC1* (B) and *NFIX* (C) mRNA expression after transduction with the indicated shRNA and control lentiviruses in Kasumi-1, MV4-11 and Fujijoka cell lines, respectively. Note that Fujijoka cells express high levels of *FOXC1* and were only used to test the functionality of our lentiviral construct. *FOXC1* is not highly expressed in MV4-11 cells. (D-F) Western Blots showing the efficiencies of shRNA knock-down for FOXC1 (D), NFIX (E) and POU4F1 (F). (G - I) Histogram showing doubling time of t(8;21) Kasumi-1 cells after transduction with sh*POU4F1* (G), MV4-11 cells after transduction with *shNFIX* (H) and of Kasumi-1 cells after transduction with *shNFIX* (I). (J, K): doubling times of Kasumi-1 (J) and MV4-11 cells (K) expressing a DOX inducible version of a dominant negative FOS peptide (dnFOS) (K,M) as well as empty control virus (L,O). All experiments were performed in triplicate. In all histograms n=3 \* p<0.05, \*\*p<0.01, \*\*\*p<0.001. Error bars show 95% confidence intervals. (L) Pictures of representative colonies derived from FLT3-ITD patient cells and CD34+ PBSCs transduced with the indicated lentiviral vectors.

## List of supplemental data files

Dataset S1: Summary of all AML mutation data

Dataset S2: Up and down-regulated genes associated with mutation groups (related to Figure 3 and Figure S4B)

Dataset S3: Number of differentially expressed genes for Figure 2C and Figure S4C

Dataset S4: List of transcriptional regulator genes showing AML type-specific expression (related to Figure S2C)

Dataset S5: Gene lists and GO terms for Figure 5 and Figure S7F.

Dataset S6: CHi-C-curated KEGG pathways and GO terms of DHS-cluster associated genes (related to Figure 3)

## Supplemental Notes with five Figures